1   **Title:** Integrating genetic regulation and single-cell expression with GWAS prioritizes causal genes
2   and cell types for glaucoma
3

4   **Authors:**
5   Andrew R. Hamel[1,2,3], John M. Rouhana[1,2,3,*], Wenjun Yan[4,*], Aboozar Monovarfeshani[4,*], Xinyi
6   Jiang[5,6], Qingnan Liang[7], Puja A. Mehta[1,2,3], Jiali Wang[1,2,3], Arushi Shrivastava[1,2], Katherine
7   Duchinski[1,2,3], Tavé van Zyl[4,8], International Glaucoma Genetics Consortium (IGGC), Rui Chen[7],
8   Veronique Vitart[5], Joshua R. Sanes[4], Janey L. Wiggs[1,2,3], Ayellet V. Segrè[1,2,3,#]
9
Affiliations:
[1]Ocular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear, Boston,
MA
[2]Department of Ophthalmology, Harvard Medical School, Boston, MA
[3]Broad Institute of Harvard and MIT, Cambridge, MA.
[4]Department of Molecular and Cellular Biology and Center for Brain Science, Harvard University,
Cambridge, MA, USA
[5]MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh,
Edinburgh, UK
[6]Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine,
The University of Edinburgh, Edinburgh, UK
[7]Department of Molecular and Human Genetics, Baylor College of Medicine, TX
[8]Department of Ophthalmology and Visual Sciences, Yale School of Medicine, New Haven, CT
23
24   * Co-second authors, these authors contributed equally
25   # Correspondence to be addressed to Ayellet V. Segrè: ayellet_segre@meei.harvard.edu

Abstract

Primary open-angle glaucoma (POAG), characterized by retinal ganglion cell death, is a leading cause of irreversible blindness worldwide; however the molecular and cellular causes are not well understood. Elevated intraocular pressure (IOP) is a major risk factor, but many patients have normal IOP. Colocalization analysis of >130 POAG and 112 IOP GWAS loci and overlapping expression and splicing quantitative trait loci (e/sQTLs) in 49 GTEx tissues and retina proposed causal genes for 60% of the loci, that were enriched in extracellular matrix organization, cell adhesion, and vascular development. Analyzing single-nucleus RNA-seq of glaucoma-relevant eye tissues, we found that the colocalizing genes were enriched in known and less well-characterized cell types, including fibroblasts in the conventional and unconventional aqueous outflow pathways; vascular cells in the anterior segment; astrocytes and Müller glia in retina and optic nerve head (ONH); and smooth muscle and vascular endothelial cells in ONH. This study nominated IOP-dependent and independent regulatory mechanisms, genes, and cell types that may underlie POAG pathogenesis.

Introduction

Primary open-angle glaucoma (POAG) is the second leading cause of irreversible blindness worldwide among people over the age of 55[1]. It is characterized by progressive optic neuropathy, caused by gradual death of retinal ganglion cells (RGCs) that transmit visual information from photoreceptors in the retina to the brain via the optic nerve[2]. Elevated intraocular pressure (IOP) is a major risk factor for POAG[3] and is primarily caused by decreased outflow of the aqueous humor, the clear fluid that fills the space in the front of the eye between the lens and cornea. Decreased outflow may be due to abnormal function of structures in the anterior segment of the eye, consisting of the trabecular meshwork (TM)[4] and Schlemm's canal (SC)[5] in the conventional outflow pathway, and the ciliary muscle and iris in the uveoscleral (unconventional) pathway[6]. However, about a third of patients with POAG display optic nerve degeneration in the absence of abnormally high IOP measurements (normal tension glaucoma (NTG))[7], and many people with elevated IOP do not develop glaucoma, suggesting that IOP-independent processes, such as increased RGC susceptibility, even in the normal IOP range, might also lead to optic nerve damage. Currently, neuroprotective therapies are lacking, and medications that reduce IOP have limited effectiveness[2].

Gaining a better understanding of the molecular and cellular causes of the disease in the front and
back of the eye could help propose novel avenues of therapy.

A recent multi-ethnic genome-wide association study (GWAS) meta-analysis of 34,179
POAG cases and 349,321 controls of European, Asian, and African ancestries identified 127 risk
loci associated with POAG, explaining ~9% of POAG heritability, and a meta-analysis of the
European subset identified 68 loci, some of which were not found in the cross-ancestry meta-
analysis[8]. A GWAS meta-analysis of IOP performed on 139,555 individuals, primarily of European
descendant[9], has identified 133 independent associations in 112 loci, largely overlapping with two
other studies[10,11]. The IOP variants' effect sizes and direction of effect are highly correlated with
their effect on POAG risk[8,9], and together they explain 9-17% of IOP heritability. Vertical-cup-to-
disc ratio (VCDR), central corneal thickness, and corneal hysteresis, a measure of the viscoelastic
damping of the cornea, have also been associated with POAG; large GWAS meta-analyses have
uncovered 70-200 genetic associations for these traits[12–23].

Identifying the causal genes and cell types underlying the genetic associations with POAG
and its related traits is challenging; as with other complex traits, the majority of associated variants
lie in noncoding regions and due to linkage disequilibrium (LD), they often tag multiple variants and
genes, making it difficult to pinpoint the implicated causal gene(s) from sequence alone.
Furthermore, genetic regulatory effects in relevant ocular tissues are limited and have not yet been
measured at cellular resolution in the eye. However, using single cell or single nucleus RNA-
sequencing, human cell atlases and cellular level transcriptomes have been created for several
non-diseased POAG-relevant eye tissues, including retina[24,25], the aqueous humor outflow
pathway[26,27], and six tissues in the anterior chamber[28].

The Genotype-Tissue Expression (GTEx) Project has identified expression quantitative trait
loci (eQTLs) and splicing QTLs (sQTLs) in 49 (non-ocular) tissues[29], which have been found to be
enriched for genetic associations in relevant tissues with a range of complex diseases and traits[29–
31]. eQTLs were recently identified in human peripheral retina[32,33] that contain RGCs. Since many
of the GTEx tissues contain cell types that could serve as proxies for the pathogenicity of glaucoma
(e.g., neuronal cells in brain as a proxy for RGCs or endothelial cells in artery as a proxy for
Schlemm's canal), and e/sQTLs are largely shared across tissues[29], we postulate that e/sQTLs in
GTEx tissues could help uncover causal mechanisms and genes underlying at least part of the
genetic associations with glaucoma.

In this study, we combined e/sQTLs, single-cell expression data from the glaucoma-relevant
eye tissues and pathway information with POAG and IOP genetic associations to identify a high
confidence set of genes, pathways, and cell types that may play an important role in POAG etiology.

We applied two Bayesian-based colocalization methods, eCAVIAR[34] and *enloc*[35] that test whether
co-occurring GWAS and e/sQTL signals are tagging the same causal variant/s to all known POAG
and IOP GWAS loci and all intersecting e/sQTLs from 49 GTEx tissues and retina. This identified
potential causal genes and the e/sQTL direction of effect on POAG risk and IOP levels for ~60%
of the loci. These genes were enriched in both previously proposed and new biological processes
that may influence POAG risk. To identify key ocular cell types for POAG pathogenesis, through
which the proposed POAG or IOP genes may be exerting their causal effect, we extended a method
we recently developed, called ECLIPSER (Enrichment of Causal Loci and Identification of
Pathogenic cells in Single Cell Expression and Regulation data)[36,37], to e/sQTL-colocalizing genes.
ECLIPSER tests whether genes mapped to GWAS loci of a given complex disease or trait are
enriched for cell type-specific expression in single cell RNA-seq data of a given tissue, compared
to thousands of GWAS loci of unrelated traits. Applying this approach to POAG and IOP e/sQTL-
colocalizing genes and single-nucleus expression data of the anterior segment, retina, and optic
nerve head, we identified known and less well-established pathogenic cell types for POAG, which
suggested both IOP-dependent and neuroprotective pathways. Finally, we tested whether POAG
and IOP associations beyond genome-wide significance were enriched among e/sQTLs in GTEx
tissues and in retina, and estimated the number of trait associations likely to have a regulatory
effect on the traits using an empirical q-value approach. We found significant enrichment in multiple
tissues, which suggested over a thousand new genetic regulatory effects on POAG and IOP.

Results

Overview of approach and methods. We applied the following analytical steps to known GWAS
loci and genome-wide association summary statistics of POAG and its major risk factor, elevated
IOP, to identify genes, regulatory mechanisms, pathways, and cell types that significantly affect
POAG risk. First, to propose putative causal genes that may underlie genome-wide significant
POAG and IOP GWAS loci, we applied two colocalization methods, eCAVIAR[34] and *enloc*[35], to
each GWAS locus and all overlapping *cis*-eQTLs and *cis*-sQTLs in 49 GTEx tissues (release v8[29])
and *cis*-eQTLs in peripheral retina[32] (Fig. 1a and Methods). These Bayesian-based methods
assess the probability that overlapping GWAS and e/sQTL signals are tagging the same causal
variant/s, accounting for local LD and allelic heterogeneity, using slightly different fine-mapping and
colocalization approaches (Methods). Second, to identify biological or physiological processes that
may be enriched for the proposed causal genes, we applied gene set enrichment analysis to all
POAG and IOP colocalizing genes and known signaling and metabolic pathways, gene ontologies,

and mouse phenotype ontologies, using *GeneEnrich*[30] (Fig. 1b and Methods). Next, to identify key

pathogenic cell types through which the colocalizing genes may be mediating their effect on POAG

and IOP, we extended a method we recently developed, ECLIPSER[36,37] to the GWAS-e/sQTL

colocalizing genes (Fig. 1c and Methods). ECLIPSER tests whether the expression of genes

mapped to GWAS loci is enriched in specific cell types compared to a null distribution of GWAS

loci associated with thousands of traits unrelated to ocular diseases which were compiled from

Open Targets Genetics (Methods). Briefly, for each trait, tissue, and cell type combination, each

POAG or IOP GWAS locus was scored as the fraction of cell type-specific genes mapped to the

locus based on e/sQTL colocalization analysis (Methods). Genes were mapped to the null set of

GWAS loci based on LD between the GTEx or retina e/sQTLs and the lead GWAS variants, and

the loci were similarly scored for cell type specificity. Cell type-specific enrichment of the GWAS

locus sets of POAG, IOP and additional related traits was assessed against an LD-independent

null distribution, using a Bayesian Fisher's exact test. Genes mapped to the GWAS loci driving the

enrichment signal in a specific cell type were proposed to influence the given trait in the

corresponding cell type. We applied this method to several ocular tissues relevant to the

pathogenesis of glaucoma: six tissues from the anterior segment, including the outflow pathway

and ciliary body, retina, and optic nerve head. We found significant enrichment of POAG and IOP

genes in specific cell types in both the front and back of the eye that were tested for enrichment in

biological pathways compared to a background of genes expressed in a matching GTEx or retina

tissue (Methods). Finally, we used *QTLEnrich*[30] to test whether POAG and IOP genetic

associations, beyond genome-wide significance, were enriched among eQTLs and sQTLs in GTEx

and retina tissues, while controlling for confounding factors[29] (Methods). In cases where enrichment

was found, the number of eQTLs and sQTLs proposed to contribute to POAG risk and IOP variation

was estimated using an empirical true positive rate estimation approach (Fig. 1d and Methods). All

software and tools developed for this analysis were released on GitHub (see URLs).

Colocalization analysis of POAG and IOP GWAS loci with e/sQTLs. To identify a

comprehensive set of putative causal genes for POAG and IOP, we applied the colocalization

methods, eCAVIAR[34] and *enloc*[35], to 127 POAG loci from a large cross-ancestry GWAS meta-

analysis[8] (POAG CA), 68 POAG loci from a European subset meta-analysis[8] (POAG EUR), and

133 IOP loci from a primarily European GWAS meta-analysis[9] (IOP) (variant list in Supplementary

Table 1; Methods). All *cis*-eQTLs and *cis*-sQTLs in any of the 49 GTEx tissues (v8)[29] and *cis*-eQTLs

in peripheral retina[32,33], whose e/sVariants overlapped with each GWAS locus LD interval were

tested (Methods). The results are presented per trait and colocalization method in Supplementary

Tables 2-7 and summarized in Supplementary Table 8, filtering out potential false positives (flagged

in last column in Supplementary Tables 2-7; see Methods and examples in Supplementary Fig. 1).

We defined a "comprehensive set" of putative causal genes and regulatory mechanisms for POAG

and IOP as those e/sGenes that were significant with at least one of the colocalization methods

(Colocalization posterior probability (CLPP) > 0.01 for eCAVIAR, and regional colocalization

probability (RCP) > 0.1 for *enloc* per the methods' recommendations[34,35] (Methods); Supplementary

Table 8). A "high confidence set" of proposed causal genes was defined based on significant

colocalization with both methods (Table 1 and Supplementary Table 9). Of note, we found that the

number of significantly colocalizing e/sGenes per tissue significantly correlated with tissue sample

size (coefficient of determination R^2=0.72, P=1x10^{-14}, Supplementary Fig. 2) that is also associated

with number of detected e/sQTLs per tissue[29], suggesting that e/sQTL discovery power is a driving

factor in tissue identity of the colocalizing e/sQTLs. We therefore primarily considered the causal

genes proposed by the colocalization analysis in downstream analyses and not the associated

tissues.

We found that 58% of all GWAS loci tested significantly colocalized with at least one eQTL

and/or sQTL based on eCAVIAR and/or *enloc*: 60% (76) of 127 cross-ancestry POAG GWAS loci,

53% (36) of the 68 European POAG loci and 59% (79) of the 133 IOP loci (Fig. 2a and

Supplementary Table 10). Two-fold more GWAS loci colocalized with ≥1 eQTL than with ≥1 sQTL

(54.6% vs. 28.4%), likely due to the larger discovery rate of eQTLs compared to sQTLs in GTEx[29].

For 21% of the POAG and IOP GWAS loci (69 loci total), significant colocalization was found for

the same e/sGene with eCAVIAR and *enloc* ('high confidence set' listed in Table 1 and

Supplementary Table 9). These high confidence genes included *TMCO1* (eQTL and sQTL),

CDKN2B-AS1 (sQTL), *GAS7* (eQTL), and *LMX1B* (eQTL), which colocalized with the largest

association signals for both POAG and IOP GWAS loci (Table 1, Supplementary Fig. 3-6, and

Supplementary Table 9). Hereafter, all downstream analyses are based on the comprehensive set

of mapped genes.

The GWAS-e/sQTL colocalization analysis significantly reduced the number of putative

causal genes per GWAS locus for POAG and IOP from an average of 22.8 ± 1.8 genes tested per

LD interval (range: 3-166, median=15) to an average of 3.5 ± 0.4 genes per locus (range: 1-36,

median of 1 or 2 genes per locus per trait; Fig. 2b,c and Supplementary Table 11). eQTLs and

sQTLs nominated an average of 3 and 2 causal genes per locus, respectively, with partial overlap

of target genes between the colocalizing eQTLs and sQTLs (Fig. 2c and Supplementary Table 8).

A single causal gene was proposed for 80 (42%) of the POAG and IOP loci with significantly

colocalizing e/sQTLs (Supplementary Tables 12 and 13), 49 (61%) of which are the nearest gene

to the lead GWAS variant. In 30.3% (23/76), 16.7% (6/36) and 31.7% (25/79) of the POAG CA, POAG EUR and IOP GWAS loci, respectively, with significant colocalization results, the colocalizing e/sGenes were not the nearest gene to the lead GWAS variant, as observed for other complex traits[29,30,38]. This emphasizes the importance of using e/sQTLs to prioritize putative causal genes implicated by GWAS loci. In total, 228, 118, and 279 genes, including previously suggested and novel ones, are candidate causal genes for POAG CA risk, POAG EUR risk, and IOP variation, respectively (Supplementary Table 14), with a total of 459 genes proposed from the combined datasets.

Noncoding genes proposed as contributors to POAG risk. While the majority of colocalizing e/sGenes are protein coding (60-72% per trait), noncoding RNA genes make up 18-20% of the proposed causal genes for POAG and IOP loci (Fig. 2d and Supplementary Table 15), half of which are lincRNAs and half antisense genes. Noncoding genes were proposed as a sole potential causal gene for 10 POAG or IOP loci, including the lincRNA *LINC01948* in POAG cross-ancestry locus rs112142644 on chromosome 5, and *RP11-217B7.2*, a lnc-ABCA1-1:1 lincRNA, in the shared POAG and IOP locus on chromosome 10 (rs2472494 and rs2472493, respectively) (Supplementary Table 8). We further found that e/sQTLs acting on 14 pairs of protein coding genes and their corresponding antisense gene colocalized in the same GWAS locus, including *HLA-F* and *HLA-F-AS1* with POAG risk, *LPP* and *LPP-AS2* with IOP levels, and *MAPT* and *MAPT-AS1* with both POAG and IOP (Supplementary Table 16).

Colocalizing e/sGenes of top POAG and IOP GWAS loci and direction of regulatory effect on disease risk. In addition to prioritizing causal genes and regulatory mechanisms that may contribute to POAG and IOP, e/sQTL-GWAS fine-mapping and colocalization analysis proposes the direction of effect of gene expression or splicing on disease risk or trait variation (examples for top POAG and IOP GWAS signals in Fig. 3 and Supplementary Fig. 3). For example, of 13 or 27 e/sGenes tested for the second strongest association with POAG (rs2790053, odds ratio (OR)=1.35) and the top IOP association (rs116089225, beta=-0.744), respectively, an eQTL and sQTL acting on *TMCO1*, a gene that encodes a calcium channel localized to the endoplasmic reticulum, and an eQTL acting on *TMCO1*'s antisense, *RP11-466F5.8*, in the opposite direction, colocalized with POAG (CLPP=0.92-1) and IOP (CLPP=0.87-1) association signals (Fig. 4a-e and Supplementary Fig. 4). Decreased expression of *TMCO1* and increased expression of *RP11-466F5.8* are proposed to lead to increased IOP levels and increased risk of POAG (Fig. 4, Supplementary Fig. 4, and Supplementary Table 8). Furthermore, an alternative splice donor site

in exon 4, the first exon in the *TMCO1* mRNA in GTEx Cells Cultured fibroblasts, which leads to a

longer exon 4 (Fig. 4f,g), is associated with decreased POAG risk (Supplementary Tables 2 and

8). Other examples include *ANGPT1* and *ANGPT2*, involved in vascular biology, whose increased

expression is proposed to reduce IOP levels (Supplementary Fig. 7 and Supplementary Table 8).

Interestingly, the eQTL acting on *ANGPT1* in Brain cerebellar hemisphere colocalized (RCP=0.23)

with the secondary IOP signal rs4496939 (chr8:107422472:A:G, beta = -0.118, P=2.7x10^{-18};

Supplementary Fig. 7c,d) and not the strongest signal rs2022945 (chr8:107238911:G:A, beta = -

0.213, P=1.1x10^{-28}; Supplementary Fig. 7e), of the three independent signals in the locus.

Colocalizing genes for shared and distinct POAG and IOP loci. We found that of 50 overlapping

POAG and IOP GWAS loci, 39 (78%) of the loci had at least one significant colocalization result for

both traits, and in all cases at least one common gene was implicated (Supplementary Table 8 and

Table 1). In most of the cases (95%), the relative direction of effect of the colocalizing e/sQTLs on

IOP was consistent with IOP's effect on POAG risk, proposing IOP-dependent mechanisms for

POAG risk (Table 1 and Supplementary Table 8). For example, decreased *GAS7* expression or

increased *ABO* expression were associated with both increased IOP levels and increased POAG

risk (Supplementary Tables 2-8 and Supplementary Figs. 6,8). In the few cases where the direction

of effect was not consistent with IOP effect on POAG the colocalizing e/sQTLs were in different

tissues for the IOP and POAG GWAS loci.

To date, only a few loci have been found to be associated with NTG[8,39]. The strongest NTG

association (9p21) in the POAG CA (rs944801 OR=1.26) and POAG EUR (rs6475604 OR=1.3)

GWAS meta-analyses, not associated with IOP, significantly colocalized with a *CDKN2A* eQTL in

Brain Cortex, and *CDKN2B-AS1 and RP11-149I2.4* sQTLs in pituitary. In addition, a *CDKN2B*

eQTL in skeletal muscle colocalized with POAG in the EUR GWAS subset. These results imply

that increased expression of *CDKN2A* and decreased expression of *CDKN2B* may increase POAG

risk, exons 2 and 3 skipping in *CDKN2B-AS1* may increase POAG risk (Supplementary Fig. 3a and

Fig. 5), suggesting an IOP-independent molecular mechanism for POAG related to cell cycle

regulation.

Colocalizing genes in population-specific and cross-ancestry POAG loci. Most of the POAG

EUR loci (59 out of 68 loci) were found in the POAG cross-ancestry meta-analysis (Supplementary

Table 8). For 31 of these loci where a significant colocalization result was found for both the EUR

and CA GWAS, at least one common colocalizing e/sGenes was found between both GWAS. One

such example is *EFEMP1*, in which rare mutations have been associated with a mendelian form of

glaucoma[40]. Colocalization analysis suggests that skipping of exons 6 and 7 in *EFEMP1* that
encode epidermal growth factor (EGF)-like domains may be protective for POAG (Supplementary
Fig. 9). Of the nine loci found only in the POAG EUR GWAS, two loci colocalized with eQTLs acting
on several genes including genes involved in the extracellular matrix (*EMID1*) and vascular
endothelial growth (*ANGPTL2*), respectively, both of which also colocalized with IOP
(Supplementary Table 17). In addition, three associations in the POAG CA meta-analysis
demonstrated significant allelic heterogeneity among the three populations (European, East Asian,
and African American). e/sQTL colocalized with two of these loci. One is the 9p21 locus rs944801
with *CDKN2A/B* described above, that was significant in the European and Asian populations, but
not the African population in which it is in lower frequency (MAF=0.073 in gnomAD (URLs);
P_heterogeneity=1.5 x 10^{-8})[8].

The other European-specific locus in POAG CA GWAS with a significant colocalization
result was the POAG association with the largest odds ratio (OR=5.47) rs74315329, which is a
nonsense mutation (p.Gln368Ter) in *MYOC*, a gene encoding myocilin and associated with
hereditary juvenile-onset open-angle glaucoma. This variant is 10-fold more common in the
European population compared to the African population and is not found in the East Asian
population (gnomAD; URLs). Testing all e/sQTL gene-tissue pairs that overlapped this locus
targeting 24 genes identified an sQTL (chr1:172398537:A:G) acting on *PIGC,* phosphatidylinositol
glycan anchor biosynthesis class C, in spleen with eCAVIAR (CLPP=0.12) or artery tissue with
enloc (artery tibial, RCP=0.34; heart atrial appendage RPC=0.26) that significantly colocalized with
the POAG CA locus (splicing event: chr1:172370311-172376554; Supplementary Table 8 and
Supplementary Fig. 10). Since the nonsense variant in *MYOC* is likely the primary causal variant
in the locus, we tested whether a secondary haplotype may exist in the locus and, if so, if it
colocalizes with the *PIGC* sQTL. We performed association testing of all variants in the GWAS
locus LD interval conditioning on the lead POAG variant rs74315329 using COJO (Methods), and
found two low frequency, intronic variants that passed genome-wide significance
(chr1:171531082:A:G EUR MAF=0.0036 and chr1:170716994:A:C EUR MAF=0.002) and another
LD-independent signal (chr1:172398537:A:G, POAG GWAS conditional P=1.08x10^{-6}, EUR
MAF=0.075 in gnomAD) that passed Bonferroni correction for the number of variants tested in the
locus (P<5.87x10^{-6}) (Supplementary Table 18). We next tested whether the residuals of this
secondary signal, which are independent of the locus' lead variant rs74315329, colocalized with
any of the e/sQTL-tissue pairs in the locus using eCAVIAR and *enloc*. We found suggestive
significance (CLPP=0.009) for the POAG LD-independent signal chr1:172398537:A:G and the
same *PIGC* sQTL in spleen as above (chr1:172370311-172376554), as well as for a *PRRX1* eQTL

(CLPP=0.01) with eCAVIAR (Supplementary Tables 19-20), and significant colocalization for the
same *PIGC* sQTL in several tissues with *enloc* (maximum RCP=0.13) (Supplementary Tables 21-
22). *Enloc* also found significant POAG colocalization for another sQTL acting on *PIGC* (max
RCP=0.22, chr1:172376636-17237813) and for *PIGC* eQTLs (RCP=0.14) in several tissues
(Supplementary Tables 21-22). These results suggest that decreased exon 2 skipping in *PIGC*
(Supplementary Fig. 10) or increased *PIGC* expression may lead to increased POAG risk. In the
single cell analysis below, we found that *PIGC* is among 10 colocalizing POAG genes enriched in
oligodendrocytes in the optic nerve head (FDR=0.03; Supplementary Fig. 14c,d).

Enrichment of POAG and IOP colocalizing e/sGenes in biological processes. To gain
biological insight into ways the implicated genes might contribute to pathogenesis, we next asked
whether the target genes of all the colocalizing e/sQTLs with POAG CA, POAG EUR, or IOP GWAS
loci were enriched in specific biological pathways, gene ontologies, or mouse phenotype ontologies
using *GeneEnrich* (Methods). Genes that colocalized with POAG CA loci were significantly
enriched in elastic fiber formation (Empirical P-value (P)$<1\times10^{-5}$, false discovery rate (FDR)<0.001)
and extracellular matrix organization (P=3×10^{-5}, FDR=0.012) correcting for multiple hypothesis
testing, and displayed nominal enrichment (P<0.05) in the transforming growth factor beta (TGF)
receptor signaling pathway (P=3×10^{-4}) and abnormal eye morphology (P=2.6×10^{-3}), amongst others
(Supplementary Table 23 and Supplementary Fig. 11a,b). No significant enrichment was found at
FDR<0.1 for e/sGenes colocalizing with POAG EUR loci. Top ranked nominal enrichment (P <
4×10^{-3}) for POAG EUR loci was found in cellular senescence and cell cycle processes (e.g., Cyclin
D-associated events in G1), lipid related processes, such as apolipoprotein binding and decreased
circulating high-density lipoprotein cholesterol level, and retina or neuronal related processes,
including abnormal retina morphology, abnormal sensory neuron innervation pattern, and negative
regulation of axon extension involved in axon guidance, amongst others (Supplementary Table 24
and Supplementary Fig. 11c,d).

For the IOP genes significant enrichment (P=2×10^{-5}, FDR=0.025) was found in
transcriptional regulation by *VENTX*, a gene that encodes a homeodomain-containing transcription
factor (Supplementary Table 25 and Supplementary fig. 11e). *VENTX* and its IOP-colocalizing
target genes driving the gene set enrichment signal (*ANAPC1*, *ANAPC7*, *AGO4*, *MOV10*, *TCF7L2*)
were most highly expressed in immune cell types, lymphocytes and macrophages, in the single cell
anterior segment and optic nerve head described below (Supplementary Fig. 11f). The IOP genes
were also significantly enriched (FDR<0.15) in blood vessel morphogenesis and vasculature
development, regulation of cytoskeletal organization, negative regulation of cellular component

organization, and adherens junction (Supplementary Table 25 and Supplementary Fig. 11e). Since

colocalization with multiple e/sQTLs was found for two loci in the HLA region on chromosome 6

(2.78 Mb apart) associated with POAG and IOP (29 and 35 e/sGenes, respectively), likely due to

high LD in the HLA region, we removed this region from the gene set enrichment analysis above

to avoid inflating the results due to a single locus. When kept in, the endosomal vacuolar pathway,

interferon gamma signaling, antigen presentation folding assembly and peptide loading of class I

MHC, negative regulation of natural killer cell mediated immunity, and cell aging were significantly

enriched (FDR<0.1) for POAG genes (Supplementary Table 26), in addition to the gene sets above.

The colocalizing POAG and IOP genes driving the gene set enrichment signals are listed in

Supplementary Tables 23-26.

Identifying pathogenic cell types for POAG and related ocular traits. To further relate the

implicated genes to pathogenic mechanisms and cell types, we next tested whether the expression

of the e/sGenes that colocalized with POAG or IOP or that mapped to GWAS loci of several other

related traits (listed in Supplementary Table 27) was enriched in specific cell types in key eye

tissues implicated in the pathophysiology of POAG: the anterior segment of the eye, where

impaired aqueous humor outflow can lead to elevated IOP, the retina, where death or dysfunction

of RGCs lead to POAG, and the optic nerve head, where local compression can cause axonopathy.

We first applied ECLIPSER[36,37] (see Methods) to 228, 118, and 279 e/sGenes that colocalized with

POAG CA, POAG EUR and IOP GWAS loci, respectively (Supplementary Table 8), and to cell

type-specific expression from single nucleus (sn) RNA-seq of (i) 6 tissues from the anterior

segment: central cornea, corneoscleral wedge (CSW), trabecular meshwork (TM) and Schlemm's

canal, iris, ciliary body (CB), and lens[28], (ii) the peripheral and macular retina, and (iii) the optic

nerve head (ONH) and adjacent retina[41], all taken from non-diseased human eyes (see Methods

and Supplementary Tables 28-30). The cell type enrichment results are summarized in

Supplementary Table 31.

In the anterior segment, we found significant enrichment (tissue-wide FDR<0.1) for POAG

EUR loci in fibroblasts derived from the ciliary muscle (present in CB, CSW and TM[28]), that were

annotated as ciliary fibroblasts in van Zyl *et al.*[28], and fibroblasts derived from the iris root (present

within the iris[28]), annotated as iris fibroblasts[28] (Supplementary Table 31 and Fig. 5a,b). The ciliary

muscle and iris are key tissues involved in the unconventional outflow pathway. These fibroblasts

were also detected histologically within the TM where all three tissues meet and interweave at the

iridocorneal angle[28], implicating the conventional aqueous outflow pathway as well. Fig. 5c shows

the e/sGenes driving the POAG EUR enrichment signal in ciliary fibroblasts. The POAG EUR genes

were only modestly enriched in fibroblasts derived predominantly from the TM tissue (annotated as

TM fibroblasts[28]) (FDR=0.18). We found supportive nominal enrichment (P<0.05, FDR<0.25) for

e/sGenes that colocalized with POAG CA loci in the ciliary (Supplementary Fig. 12) and iris

fibroblasts, as well as cornea and TM fibroblasts, vascular endothelium (cluster 2 derived from TM,

CSW and CB tissues[28]), and lens epithelium (Supplementary Table 31 and Fig. 5a,d). Genes

whose e/sQTLs colocalized with IOP GWAS loci were significantly enriched (FDR<0.1) in pericytes

(cluster 2 that localizes to the CSW[28]), TM fibroblasts, and ciliary fibroblasts, and modestly enriched

(FDR<0.2) in lens equator epithelium, vascular and lymphatic endothelium, and Schlemm's canal,

whose dysfunction can lead to elevated IOP[42] (Supplementary Table 31 and Fig. 5e).

Clustering of the top ranked anterior segment cell types (P<0.05) for POAG and IOP,

separately, based on the overlap of genes driving the cell type enrichment, suggests two cell

classes affecting POAG - fibroblasts populating the unconventional and conventional outflow

pathways and vascular endothelium, and three cell classes for IOP - fibroblasts in both outflow

pathways, pericytes, and lymphatic endothelial cells (Fig. 5f,g). Between 45-78% of the genes

driving the POAG enrichment signals in the outflow fibroblast cell types are common between the

different fibroblasts (Fig. 5f), suggesting both shared and distinct genes acting in the conventional

and unconventional outflow pathways. The IOP genes driving the enrichment signal in pericytes

(Fig. 5h,i) were largely distinct from those enriched in vascular and fibroblast cell types (overlap 7-

33%; Fig. 5g), and were enriched in vasculature development (P=3x10^{-5}, FDR=0.075;

Supplementary Table 33), while the IOP genes driving the enrichment in TM fibroblasts

(Supplementary Fig. 12c,d) were highly shared with the IOP genes enriched in ciliary and iris

fibroblasts (overlap 64-88%; Fig. 5g). Notably, the enrichment of IOP genes in pericytes was

specific to IOP; half of the IOP loci driving the enrichment signal in pericytes were not associated

with POAG risk (asterisks in Fig. 5h).

We next tested for enrichment of POAG and IOP colocalizing e/sGenes in retina snRNA-

seq data (Supplementary Table 28) (Methods). We found significant enrichment of POAG CA

genes in astrocyte and Müller glia cells in retina (FDR<0.059; Supplementary Table 31 and

Supplementary Fig. 13). POAG EUR and IOP genes did not display significant cell type enrichment

in the retina that passed multiple hypothesis correction; the IOP genes were nominally enriched in

astrocytes (P=0.027, FDR=0.43; Supplementary Fig. 13). Half of the POAG CA genes driving the

enrichment in astrocytes and Müller glia cells were common (Supplementary Fig. 13d,e),

suggesting shared and distinct processes. The POAG genes driving the enrichment in astrocytes

were enriched in MAPK6/MAPK4 signaling (P=1x10^{-5}, FDR=0.01) and regulation of cell projection

organization (P=3x10^{-5}, FDR=0.15) (Supplementary Table 33). The POAG CA enrichment in Müller

glia and astrocytes replicated (FDR<0.06) in a separate snRNA-seq study of the macula (Methods;
Supplementary Table 31 and Supplementary Fig. 13f).

Finally, we tested for cell type-specific enrichment in the optic nerve head (ONH) using
samples that also contained adjacent retinal tissue (Methods; Supplementary Table 30). In this
dataset, we found the strongest enrichment for POAG CA genes in astrocytes (FDR=0.005),
followed by Müller glia, smooth muscle, melanocytes, vascular endothelium, Schwann cells,
mlCones (a mixed population of M-cones and L-cones), and oligodendrocytes (FDR<0.05; Fig 6a,b,
Supplementary Table 31 and Supplementary Fig. 14). For POAG EUR genes, significant
enrichment was found in Müller glia, oligodendrocytes, and astrocytes (FDR<0.1; Fig. 6c and
Supplementary Table 31), and for IOP genes in smooth muscle, astrocytes, Schwann cells, and
vascular endothelium (FDR<0.04; Fig. 6d, Supplementary Table 31, and Supplementary Fig. 14).
These results confirm roles for astrocytes and Müller glia noted above, and reveal roles for cell
types within the ONH, e.g., oligodendrocytes, Schwann cells, and smooth muscle.

Over half of the genes driving the enrichment signal of POAG genes in astrocytes in ONH
(Fig. 6e,f) and retina tissues from separate donors were common (e.g., *DGKG, PLCE1, LPP*,
GAS7, *YAP1*, *COL11A1, and ABCA1*; Supplementary Table 31). *DGKG*, diacylglycerol kinase
gamma, whose retina eQTL colocalized (CLPP=0.96) with POAG CA association (Fig. 6g),
displayed the strongest cell type specificity in astrocytes (Fig. 6e,f). Furthermore, half the POAG
genes driving the enrichment in Müller glia in ONH and retina were shared (e.g., *PLCE1, CTTNBP2,*
YAP1, TSC22D2, CLIC5, and *TRIB2*), and mostly distinct from the astrocyte-specific genes
(Supplementary Table 31). This analysis proposes genes that may be affecting POAG risk via
changes in gene regulation in astrocytes and/or Müller glia cells. The IOP genes driving the
enrichment in smooth muscle that is unique to ONH are shown in Supplementary Fig. 14e,f; these
genes were enriched for anchoring junction and cell substrate junction cellular components
(P<2.3x10^{-4}, FDR=0.072; Supplementary Table 33). The cell type expression profiles of all POAG
CA, POAG EUR and IOP colocalizing e/sGenes is shown in Supplementary Fig. 15, and a summary
of the cell types and pathways in which each of the POAG and IOP colocalizing e/sGenes are
enriched is presented in Supplementary Tables 34-36.

To further augment the POAG and IOP enrichment analysis, we tested for cell type
enrichment of genes mapped to GWAS loci of additional glaucoma associated traits, including
vertical-cup-to-disc ratio (VCDR), cornea hysteresis, and central cornea thickness (Methods) in all
three ocular tissues (Supplementary Table 31). Since e/sQTL colocalization analysis of these traits
was beyond the scope of this paper, we mapped putative causal gene/s to the loci of these traits if
they had e/sQTLs in LD with the lead GWAS variant (Methods). In the anterior segment, genes

mapped to central corneal thickness and corneal hysteresis were most significantly enriched in
corneal fibroblasts (FDR<0.007; Supplementary Fig. 16a,b), highlighting the specificity of the
POAG and IOP gene enrichment in the outflow pathway fibroblasts. The VCDR GWAS loci from a
well-powered GWAS that used deep learning (ML) to score the characteristics of 65,680 fundus
images[12] showed significant enrichment in the TM fibroblasts from the conventional outflow
pathway (FDR=0.02; Supplementary Fig. 16c). TM fibroblasts were also the top nominally enriched
cell type for a smaller VCDR GWAS where 23,899 fundus images were manually scored by
ophthalmologists[13] (P=0.0076, FDR=0.3; Supplementary Fig. 16d). In the retina, corneal hysteresis
displayed significant enrichment in Müller glia cells (FDR=0.067; Supplementary Fig. 16e,f), and
the ML-based VCDR loci in mlCones (M-cone and L-cone photoreceptors) and GABAergic
amacrine cells (FDR=0.07; Supplementary Fig. 16g,h). In the ONH, both central corneal thickness
and corneal hysteresis displayed significant enrichment (FDR<0.1) in smooth muscle and astrocyte
(Supplementary Fig. 16i,j) and central corneal thickness also in Müller glia and Schwann cells
(Supplementary Fig. 16i). Genes mapped to VCDR loci, on the other hand, were primarily enriched
in mlCones (FDR=0.007; Supplementary Fig. 16k,l), distinct from the POAG and IOP enrichment.
Of note, the cell type enrichments of the cornea-related and VCDR traits in retina and ONH were
driven by a small number of e/sGenes (Supplementary Table 31). In summary, our cell type
enrichment analysis proposed known and new causal genes for POAG and related ocular traits
that may be affecting glaucoma susceptibility through specific cell types in the anterior and posterior
parts of the eye (Supplementary Table 31).
462
Identifying new genetic associations of regulatory effects on POAG and IOP. As the GWAS
loci discovered to date for POAG and IOP explain only a small portion of the traits' heritability, we
tested whether eQTLs and sQTLs can help identify new trait associations with modest effects
beyond genome-wide significance, not yet detected due to insufficient GWAS sample sizes. To this
end, we tested whether eQTLs and sQTLs from 49 GTEx tissues and retina eQTLs were enriched
for multiple POAG or IOP associations (GWAS P<0.05) using *QTLEnrich*[30], which adjusts for
confounding factors and tissue sample size (Methods). In cases where enrichment was found, we
estimated the number of e/sQTLs that may be true associations with POAG or IOP based on an
empirical estimation of the true positive rate (π_1), which we implemented in *QTLEnrich* (see
Methods).
We found significant enrichment of POAG and IOP associations among both eQTLs and
sQTLs in most of the 49 GTEx tissues and retina (Bonferroni-corrected P<5x10^{-4}) (Supplementary
Tables 37-39), with stronger enrichment found for IOP compared to POAG (Fig. 7a-c; One-sided

Wilcoxon rank sum test $P<1.6x10^{-8}$). Notably, the relative contribution of sQTLs to POAG risk and

IOP variation, as measured by adjusted fold-enrichment and estimated true positive rate, was larger

than the relative contribution of eQTLs to these traits (One-sided Wilcoxon rank sum test $P<1.5x10^{-11}$

and $P<0.03$, respectively; Fig. 7a,b and Supplementary Table 37-39). However, the absolute

number of eQTLs proposed to contribute to POAG risk and IOP variation (average 258 to 606; max

1205) was 2-fold larger than the number of sQTLs proposed to contribute to POAG and IOP

(average 124 to 320; max 788) (Fig. 7c and Supplementary Table 37). For POAG CA, the strongest

enrichment of hundreds of associations among eQTLs was found in brain, lymphocyte, cells

cultured fibroblast, esophagus, and artery, and among sQTLs in kidney cortex, heart atrial

appendage, brain, glands, and adipose (Fig. 7d,e,g, Supplementary Fig. 17 and Supplementary

Table 38-39). For IOP, the strongest enrichment among eQTLs was found in brain, adipose, skin,

fibroblast, and artery, and among sQTLs in brain, glands and heart atrial appendage (Fig. 7f,

Supplementary Fig. 17 and Supplementary Table 38-39). The retina eQTLs were also enriched for

POAG and IOP associations ($P<1x10^{-5}$), though not among the top-ranking tissues. While the GTEx

tissues are non-ocular tissues, many of the most strongly enriched tissues share cell types that

may be pathogenic to glaucoma. For example, glial cells in brain may share e/sQTLs also present

in astrocytes or Müller glia cells in the retina, vasculature cells in artery may be a proxy for the

lymphatic vessels in the aqueous outflow pathway, and cultured fibroblasts may share genetic

programs with the fibroblast cells in the ocular outflow pathway. In all, this analysis suggests that

over a thousand common variants that affect gene expression or alternative splicing are likely to

contribute to POAG risk and IOP variation.

Pathway analysis of e/sQTL target genes of top ranked POAG and IOP associations. To

identify the true positive POAG and IOP associations, beyond genome-wide significance, over

noise amongst the enriched e/sQTLs, and to propose potentially new causal genes and pathways,

we searched for target genes of e/sQTLs with POAG or IOP GWAS P-values below 0.05 that were

enriched in biological pathways, gene ontologies, or mouse phenotype ontologies. Our underlying

hypothesis was that genes that contribute to complex traits will cluster in a limited set of biological

processes. We applied *GeneEnrich* to a selected set of tissues per trait that displayed the highest

adjusted fold-enrichment, controlling for gene expression levels in the given tissue (Supplementary

Table 40-41). We found significant enrichment of target genes of brain hippocampus sQTLs with

top ranked POAG CA associations in mitochondrial respiratory complex I (FDR<0.05), including

NADH dehydrogenase complex assembly and mitochondrial respiratory chain complex assembly,

which included newly proposed genes for POAG (e.g., *NDUFB2, NDUFB4, NDUFAF1, NDUFAF2,*

NDUFAF6, and *ATP5SL*), and the citric acid TCA cycle (FDR=0.9) (Supplementary Table 40).
Target genes of gastroesophageal junction eQTLs with top ranked POAG associations were
enriched (FDR<0.1) in metabolic processes, including glycosaminoglycan biosynthesis keratan
sulfate and limonene and pinene degradation. Target genes of brain spinal cord eQTLs enriched
for IOP associations were enriched in cellular amino acid catabolic metabolism, in particular,
histidine metabolism (FDR=0.03), and skin eQTLs with top ranked IOP associations were enriched
in dynactin binding that is involved in moving membrane vesicles along microtubules (FDR=0.07)
(Supplementary Table 41). This analysis identified novel genes that may influence POAG risk or
IOP via regulatory effects (listed in Supplementary Table 40-41), functioning primarily in metabolic
processes. Examining other types of functional relationships, such as co-regulation or protein-
protein interactions, might help identify additional glaucoma associations and genes.
521
522   **Discussion**
523
Here we present a systematic investigation of the underlying causal mechanisms, genes
and cell types of over 130 loci associated with POAG[8,9], the most common form of glaucoma, and
over 100 loci associated with its major risk factor, elevated IOP[9]. Our analysis integrated a variety
of datasets, including expression and splicing QTLs from 49 GTEx tissues[29] and retina[29,32], single-
nucleus expression data from three glaucoma-relevant ocular tissues - anterior segment[28], retina,
and optic nerve head, and the largest to date GWAS meta-analyses for these traits[8]. Using two
QTL/GWAS colocalization methods[34,35], we prioritized putative causal genes for ~60% of the POAG
and IOP GWAS loci. A similar fraction of GWAS loci with significant colocalization results has been
found for other complex diseases and traits[29,38]. For a quarter (80) of the POAG and IOP loci, a
single gene was proposed, ten of which are noncoding genes (lincRNA and antisense), suggesting
that transcriptional and post-transcriptional gene regulation contribute to glaucoma susceptibility.
For about a third of the GWAS loci, none of the proposed causal gene/s were the nearest gene to
the lead GWAS variant, similar to that observed for other complex traits[30,38,43]. This emphasizes the
importance of using e/sQTLs or other functional assays that link regulatory regions to distal target
genes[30,44–46] to prioritize causal genes underlying common variant associations.
Integrating e/sQTLs with POAG and IOP GWAS loci proposed both previously suggested[8]
and new biological processes for these traits. The POAG colocalizing genes, which included
several known mendelian, early onset glaucoma genes (*EFEMP1*[40,47] and *LTBP2*[48]), were most
strongly enriched in extracellular matrix organization and elastic fiber formation, as previously
reported[8]. Structural changes of the extracellular matrix in both the trabecular meshwork in the

outflow pathway and the optic nerve head have been associated with POAG[49]. Regulation by the
homeodomain transcription factor, VENTX, was the most significantly enriched gene set for IOP
genes, which has not yet been associated with glaucoma. VENTX is proposed to play important
roles during embryonic patterning (by homology), including in neural crest development[50], as well
as hematopoiesis, leukemogenesis, cellular senescence and macrophage differentiation[51]. Its
strongest expression in our single cell data was in lymphocytes in the anterior segment, and
macrophages in the optic nerve head, proposing a novel link between immune-related processes
and IOP levels. Reduced circulating endothelial progenitor cells has been reported in POAG
patients[52], which could explain impaired flow mediated vasodilation in POAG[53]. Additional
processes suggested to affect IOP regulation based on gene set enrichment analysis included
vascular development, as previously suggested[9], regulation of cytoskeleton organization, and
adherens junction, a cell-cell junction whose cytoplasmic face is linked to the actin cytoskeleton,
and that allows cells to respond to biomechanical forces, biochemical signals and structural
changes in the tissue microenvironment[54]. Inhibition of adherens junction regulation in trabecular
meshwork has been shown to modestly influence IOP levels in rabbits[55]. We also found modest
enrichment of POAG genes in neuronal-related processes, including genes affecting retinal
morphology, sensory neuron innervation pattern, and regulation of axon guidance. These genes
may represent IOP-independent mechanisms, which will need to be corroborated in future GWAS
with larger numbers of normal tension glaucoma cases.

In addition to prioritizing causal genes for POAG and IOP, e/sQTLs suggest the direction of
effect of gene expression changes or alternative splicing on disease risk that could inform drug
design. In this study, we provide various hypotheses of putative causal genes and regulatory
mechanisms that may affect POAG susceptibility in an IOP-dependent or independent manner, for
experimental follow up. For example, an increase in expression or alternative splicing of *TMCO1*,
a gene that regulates the balance of calcium ions inside the endoplasmic reticulum, or a decrease
in expression of *LMX1B*, LIM homeobox transcription factor 1 beta, that is essential for several
developmental processes including the anterior segment of the eye[56], were proposed to reduce
POAG risk and IOP levels, while alternative splicing of *CDKN2B-AS1* may affect POAG
independent of IOP. An sQTL acting on *CDKN2B-AS1*, which leads to skipping of exons 2 and 3
that overlap the *CDKN2B* gene on the opposite strand, is proposed as a potential mechanism of
action for the protective signal found in this gene[57]. Skipping of these exons might render the
CDKN2B antisense less efficient in forming a complex with the *CDKN2B* RNA. Our work also
suggested a potential secondary causal gene, *PIGC* for the strongest POAG association, a
nonsense mutation in *MYOC*, a result that will need to be replicated in a larger independent POAG

GWAS. The *MYOC* mutation causes aggregation of misfolded myocilin proteins in the trabecular
meshwork, which imay lead to elevated IOP levels[58]. The enrichment of *PIGC* (that encodes an
endoplasmic reticulum associated protein) along with other POAG colocalizing genes in
oligodendrocytes in the optic nerve head suggests a secondary causal role for this locus in RGC
function.

There are several reasons why we may not have found colocalizing e/sQTLs for 40% of the
POAG and IOP loci. First, some of the causal genes or regulatory effects may be specific to regions
in the eye or rare cell types for which we do not yet have representative e/sQTLs. Second, some
genes may affect POAG or IOP by perturbing processes only active during development or under
specific conditions or stimuli, not captured in adult tissues. Third, the causal variant may be another
type of molecular QTL not tested in this study, such as e/sQTL acting in *trans* or protein QTLs.
Fourth, some of the genetic associations may be tagging deleterious protein-coding variants[8].
Finally, there are several limitations to Bayesian colocalization methodologies[59,60]. Under-
estimation of enrichment of e/sQTLs in a given tissue in GWAS hits, used as a prior in the
colocalization analysis, or GWAS loci with modest effect sizes may lead to loss of power[59].
Furthermore, the choice of genotype reference panel used to compute LD for fine-mapping of the
GWAS and QTL loci may have an effect on colocalization sensitivity. We used GTEx as our
reference panel, whose European to African sample ratio is comparable to that of the POAG cross-
ancestry GWAS, but has substantially fewer East Asian samples[29]. We do not expect this to have
a significant impact on our colocalization results as most of the POAG loci were found to be shared
across populations[8], and the fraction of loci with significant colocalization results was similar
between the POAG cross-ancestry and European subset GWAS meta-analyses.

There are caveats to consider in interpreting the colocalization results. Colocalization
analysis identifies co-occurring GWAS and e/sQTL loci likely driven by the same causal
variant/haplotype, suggesting that change in expression or splicing of the QTL target gene is causal
to the GWAS trait (vertical pleiotropy). However, we cannot rule out the possibility that the causal
effect on POAG or IOP may be through another mechanism other than change in gene expression
(horizontal pleiotropy). Approaches such as Mendelian randomization[61,62] can be used to further
support a causal effect of colocalizing e/sQTLs on POAG and IOP.

By applying a novel method (ECLIPSER) to the colocalizing e/sGenes and single nucleus
expression data from glaucoma-relevant eye tissues, we provide support for previously implicated
cell types affecting POAG development, and shed light on less well-established or novel pathogenic
cell types for POAG and IOP. One of the unique features of ECLIPSER, compared to other single
cell enrichment methods[63–67] is that it identifies cell types that are specific to a given disease or

trait, compared to a range of unrelated complex diseases and traits. Our results found that gene

expression variation in the TM cells and Schlemm's canal cells in the conventional outflow pathway,

as well as the ciliary and iris fibroblasts in the unconventional outflow pathway, may both be key

contributors to IOP regulation and POAG risk. Since the role of the unconventional outflow pathway

in IOP homeostasis remains relatively understudied compared to that of the conventional

pathway[68], these findings may encourage further avenues of investigation. Lack of enrichment in

ciliary epithelium, which is thought to be a primary producer of aqueous humor[69] suggests that

blockage of aqueous flow is more likely to affect IOP and POAG than aqueous overproduction. The

enrichment of genes that mapped to VCDR GWAS loci in TM fibroblasts suggests that the

conventional outflow pathway may have a stronger effect on optic nerve anatomy than the

unconventional pathway. Furthermore, the enrichment of IOP genes in pericytes, many of which

are not currently associated with POAG, extends our understanding of how genetic variation may

be affecting IOP in the anterior segment. Pericytes are mural cells that wrap around the endothelial

cells that line capillary blood vessels. A recent study has found reduced capillary diameter and

impaired blood flow at pericyte locations in mouse eyes with high IOP[70].

In the peripheral and macular retina and optic nerve head, we found significant enrichment

for POAG colocalizing genes in astrocyte and Müller glia cells, which replicated in an independent

snRNA-seq macula study. Astrocyte and Müller glia are two types of macroglia cells that wrap

around axons of neurons, including RGCs, and play an important role in retinal homeostasis,

including metabolic supply and structural support, maintaining the extracellular environment of the

neurons, and neurotransmitter transmission. Müller glia, the most common glial cell in the retina,

span the entire retinal layer, while astrocytes are present only in the innermost layer of the retina.

Several studies in animal models and patients with glaucoma[71–73] have found that astrocytes and

Müller glia cells become reactive at early stages of glaucomatous conditions when RGCs are intact,

suggesting a role for macroglia in the initiation and progression of glaucoma. The POAG genes

driving the astrocyte enrichment included genes enriched in extracellular matrix organization

(*COL8A2, COL11A1*), TGF-beta signaling (*SMAD6*) and sterol or lipid binding (*DGKG, MOV10,*

RORA) (Supplementary Table 34-35). Structural changes in the extracellular matrix induced by

TGF-beta2 in the optic nerve head, as with the aqueous outflow pathway, have been correlated

with POAG and have been suggested to cause impairment of optic nerve axonal transport and

neurotrophic supply that could influence RGC degeneration[49]. Of note, astrocytes have been found

to be one of the major cell types isolated from human ONH[74] and make up 20% of the cells in our

ONH dataset.

The strongest enrichment of IOP colocalizing genes was in smooth muscle cells in the ONH.
These genes were enriched for cell substrate junction and anchoring junction cellular components,
suggesting a role in cytoskeleton-associated cell-cell adhesion and cell-extracellular matrix
adhesion. These muscle cells may be part of the lamina cribrosa (LC), a mesh-like structure where
unmyelinated RGCs pass through the sclera to exit the eye, as LC cells isolated from human ONH
were found to stain for alpha-smooth muscle actin[74,75]. Cells in the LC produce extracellular matrix
proteins to support the LC structure[75], and biomechanical strain on the LC, such as from elevated
IOP, is thought to be one of the causes of RGC degeneration[76,77]. Further investigation will be
needed to determine whether the muscle cells found in our ONH single nucleus data reside in the
LC or in other structures such as blood vessels. Of note, astrocytes are the other common cell type
found in the LC dissected from human ONH[75]. The IOP genes were also enriched in vascular
endothelial cells in the optic nerve head, suggesting that vascular structural abnormalities or
functional dysregulation of blood flow to the optic nerve and retina may be an important contributor
to POAG[78]. It is also possible though that the enrichment in the ONH vascular endothelial cells is
capturing causal mechanisms acting in the vascular endothelial cells in the anterior segment that
were enriched for three quarters of the same IOP genes as in ONH (8 out of 12 genes). Notably,
we did not find significant enrichment of POAG or IOP genes in RGCs, whose cell death is the key
characteristic of glaucoma, but rather in neuronal support cells. Furthermore, while several studies
have suggested that microglia, specialized macrophage-like cells, may affect RGC survival[79], we
did not find support for a causal role of microglia in POAG susceptibility, based on our analyses. In
all, our findings in retina and ONH propose cell types and biological processes that may be viable
targets for neuroprotective therapies.

A potential limitation of our GWAS-cell type enrichment method, ECLIPSER is that it
primarily considers genes whose expression is specific to one or few cell types within a tissue, and
not genes expressed at similar levels across most or all cell types, which may also contribute to
disease risk or trait variation. Future considerations of multiple modest associations genome-wide
may increase discovery power of pathogenic cell types for glaucoma.

When considering genome-wide associations beyond the known GWAS loci, we found
significant enrichment of hundreds of new genetic regulatory effects on POAG risk and IOP
variation, suggesting a primary role for transcriptional regulation in POAG susceptibility, as
observed for other diseases[29–32]. This analysis suggested that sQTLs may have a stronger relative
effect on POAG and IOP than eQTLs, even though a larger number of eQTLs likely contribute to
POAG risk. A similar pattern was found for other complex traits[29]. The top ranked tissues with the
strongest eQTL enrichment of POAG and IOP associations: brain, fibroblasts, and artery, were in

line with our GWAS cell type specificity enrichment results. The enriched GTEx e/sQTLs likely

capture shared genetic regulation with the actual pathogenic tissues for glaucoma, partly explained

by GTEx tissues containing cell types that are relevant to POAG pathogenicity (e.g., fibroblasts in

outflow pathway or neuronal support cells in retina), and partly due to shared regulation across cell

types and tissues. It is also possible that dysregulation in some of the non-ocular tissues may

themselves affect POAG risk. Retina eQTLs, while significantly enriched for POAG associations,

did not display the strongest fold-enrichment. This may be because the cell types in retina affecting

POAG risk may not be highly abundant in the tissue and thus their eQTLs may not be well captured

by bulk tissue RNA-seq. One such example may be the Müller glia cells suggested by our single

cell analysis to be pathogenic for POAG.

In conclusion, our work has generated new insights into POAG mechanisms, which could

inform the development of novel therapies targeting IOP reduction and neuroprotection. By

integrating genetic regulation and single cell expression in glaucoma-relevant ocular tissues with

GWAS summary statistics we have identified known and new causal genes and biological

processes; proposed key ocular cell types that may be pathogenic for glaucoma; and provided

evidence for the existence of hundreds of novel genetic associations of regulatory effects for

glaucoma. In the future, detection of e/sQTL in relevant eye tissues and at the cellular level[80,81] is

expected to provide a more complete picture of the causal molecular and cellular mechanisms of

POAG risk and IOP variation. The approach and methods presented in this study can be applied

to any complex disease or trait with available GWAS summary statistics and single cell data from

relevant tissues or cell types.

Methods

GWAS datasets. We applied colocalization and fine-mapping analysis to 127 GWAS loci identified

in the cross-ancestry POAG GWAS meta-analysis of 34,179 cases and 349,321 controls from

European, African, and East Asian populations[8], 68 GWAS loci from the GWAS meta-analysis of

the European subset of 16,677 POAG cases and 199,580 controls[8], and 133 LD-independent

GWAS variants in 112 loci from the IOP GWAS meta-analysis of 139,555 primarily UK Biobank

samples[9]. The GWAS meta-analysis summary statistics, which included p-value, effect size and

standard error, were obtained from the corresponding studies. Chromosome positions were lifted

over from genome build 37 (hg19) to hg38. Association results on chromosome X were only

available for the POAG GWAS meta-analyses (cross-ancestry and European subset).

GTEx and EyeGEx QTL datasets. *cis*-eQTLs and *cis*-sQTLs from 49 tissues from GTEx release v8[29] and *cis*-eQTLs from peripheral retina[32] were used in this study. Summary statistics of all variant-gene e/sQTL pairs tested in each of the 50 tissues, the significant e/sGenes and e/sVariants at FDR<0.05, and the gene expression levels and LeafCutter[82] values are available for download from the GTEx portal (URLs). The summary statistics of all variant-gene pairs tested per gene and tissue was used as input to the colocalization analysis, and the LocusZoom[83] and LocusCompare plots (URLs). Plots of exon and exon junction read counts were taken from the visualizations on the GTEx portal (URLs). Gencode versions 26 and 25 were used for the GTEx v8 and EyeGEx studies, respectively.

Colocalization analysis. To identify a high confidence set of genes and regulatory mechanisms that may be mediating the functional mechanisms underlying known genetic associations with POAG and IOP, we applied two Bayesian-based colocalization methods: eCAVIAR[34] and *enloc*[35]. These methods assess the probability that co-occurring GWAS and e/sQTL signals are tagging the same causal variant or haplotype and are applied to GWAS and QTL summary-level statistics enabling the analysis of large, well-powered GWAS meta-analyses, for which genotype data are not available. For the *enloc* analysis, DAP-G[35] was used to perform fine-mapping of GWAS and e/sQTL loci to estimate the posterior probabilities of each variant in each locus being the causal variant, while eCAVIAR has the fine-mapping feature built in. We applied the two colocalization methods to 127 POAG GWAS loci from a recent cross-ancestry GWAS meta-analysis, 68 POAG GWAS loci from the European subset meta-analysis, and 133 independent IOP variants (112 loci) from a primarily European study (described above). Z-scores from the GWAS and GTEx e/sQTL studies, computed as the effect size (beta) divided by the standard error of the effect size for each variant, were used as input into eCAVIAR and the fine-mapping method, DAP-G. For the retina eQTLs, we computed the z-score from the variant association p-values assuming a chi-square distribution with 1 degree of freedom.

All GWAS loci were tested for colocalization with all eQTLs and sQTLs from 49 GTEx tissues[29] and peripheral retina[32] that had at least 5 e/sVariants (FDR<0.05) within the GWAS locus LD interval. An LD window around each lead GWAS variant was defined as the chromosome positions on either side containing variants within $R^2 > 0.1$, determined using 1000 Genomes Project Phase 3[84] as the reference panel, and extending an additional 50kb on either side. For the IOP and POAG EUR loci, LD was computed using only the European samples in 1000 Genomes Project, while for the cross-ancestry POAG loci, LD was computed using the European, African, and East Asian samples in 1000 Genomes. If a GWAS variant was not found in 1000 Genomes,

an LD proxy variant (R^2 > 0.8) was searched for in GTEx, and if not found, the nearest variant was

used. The interval boundaries and number of variants tested are reported in Supplementary Tables

2-8. eCAVIAR and enloc analyses were applied to all common variants (MAF>1%) that fell within

the GWAS LD intervals and were present in both the GWAS and e/sQTL studies. The effect allele

of the variants in each GWAS was aligned relative to the alternative (ALT) allele, as done in GTEx

and EyeGEx.

eCAVIAR analysis. eCAVIAR[34] is a probabilistic model that estimates the posterior

probability that the same variant is causal in overlapping GWAS and e/sQTL signals, accounting

for the uncertainty of LD and allelic heterogeneity. It simultaneously performs statistical fine-

mapping on the GWAS and e/sQTL signals to optimize integration. For the eCAVIAR analysis, we

assumed at most two independent causal variants per locus[29]. Only variants present in both the

GWAS and QTL studies were analyzed. LD matrices with R^2 values between all pairwise variant

comparisons per locus were computed for each GWAS locus LD interval (defined above), using

the GTEx whole genome sequencing (WGS) data from release v8 as the reference panel, and were

used for fine-mapping of all variants in the GWAS and e/sQTL loci. The genotypes from all 838

GTEx donors in v8[29], consisting of European (84%), African (12.3%), and East Asian (1.4%)

ancestries, were used for the LD calculations for the cross-ancestry POAG loci, and the European

subset (715 donors) was used for the European POAG and IOP loci. Due to computational

limitations, for GWAS LD intervals with more than 1000 variants, variants with e/sQTL p-values

below 0.05 were filtered out. GWAS-e/sQTL-tissue combinations with a colocalization posterior

probability (CLPP) above 0.01 were considered significant in this study, based on previous

simulations that suggested a high true positive rate and low false positive rate at CLPP > 0.01[34].

Colocalization analysis of the retina eQTLs was only performed using eCAVIAR.

***enloc* analysis.** *enloc* (Enrichment estimation aided colocalization analysis)[35] is a Bayesian

hierarchical model used to determine the probability of colocalization of molecular QTLs with

GWAS signals, that consists of three steps: estimation of enrichment levels of QTLs among the

GWAS hits, fine-mapping using an empirical Bayes method (DAP-G)[35], and colocalization analysis

that estimates a regional colocalization probability (RCP) that is the sum of SNP-level colocalization

probabilities (SCPs) of all variants per GWAS locus. *enloc* does not limit the potential number of

independent causal variants. To estimate the posterior probability of causality (posterior inclusion

probabilities (PIPs)) of variants in the GWAS loci we applied DAP-G (URLs) to all variants in the

LD intervals defined above for the POAG cross-ancestry, POAG European, and IOP loci. For

several loci, we restricted the maximum model size parameter (-msize) to 5, which represents the

number of independent association clusters, due to memory limitations. DAP-G outputs were post-

processed, selecting all fine-mapped variants and their associated cluster number and PIP for each GWAS locus which were inputted into *enloc*. For the GTEx e/sQTLs, we used similar DAP-G fine-mapping results published for all e/sQTLs in 49 GTEx tissues that were computed using the European subset of GTEx samples[38]. LD matrices were computed per GWAS locus using all GTEx WGS samples for the POAG cross-ancestry loci and the subset of European individuals in GTEx for the POAG EUR and IOP loci, as the reference panel. We used an LD-threshold of 0.75 (-ld_control) that determines the strength of genotype correlation between variants that belong to a given fine-mapped signal cluster, as used in the GTEx European subset e/sQTL analysis[38]. Finally, we applied *fastEnloc*[85] (URLs), a faster implementation of *enloc*, to the fine-mapped results of the GWAS loci and overlapping GTEx e/sQTLs. Only e/sVariants included in a 25% or greater credible set of causal variants and that overlapped with the GWAS variants were analzyed in the colocalization analysis. The colocalization analysis outputted RCP values above 1×10^{-4} for each tested GWAS locus, trait, tissue, and gene or gene-intron excision cluster combination. An RCP above 0.1 was considered significant in this study, based on the method's recommendation[35,59]. In Supplementary Tables 5-7 we listed the set of variants included in the 95% credible set for each independent GWAS locus, e/sQTL, gene and tissue colocalization signal (cluster). In cases where a significantly colocalizing sQTL that regulates an intron cluster mapped to more than one gene, all target genes were reported as significant.

Quality control and summary across the two colocalization methods. In inspecting the significant colocalization results and plotting the $-\log_{10}$(P-value) of the GWAS signal versus the $-\log_{10}$(P-value) of the e/sQTL signal, we noticed multiple cases where the GWAS P-values and/or the e/sQTL P-values of the variants with significant colocalization posterior probabilities (CLPP>0.01 and/or RCP>0.1) were not significant (e.g., association P>0.05) or did not pass multiple hypothesis correction (see examples in **Supplementary Fig. 1**). Thus, to remove potential false positives, we filtered out variant, gene, tissue, trait combinations where the e/sVariant with a significant colocalization result had a GWAS p-value above 1×10^{-5} or whose e/sQTL p-values was above 1×10^{-4} and/or did not pass FDR<0.05 (FALSE in column 'Pass_QC_QTL_FDR05_P1E04_GWAS_P1E05' in **Supplementary Tables 2-7)**. We chose a GWAS $P<10^{-5}$ cutoff, as it has been suggested that in many cases the lead GWAS variant is not the causal variant, but instead tagging the causal variant that may have not reached genome-wide significance[86]. We defined two sets of putative causal genes and regulatory mechanisms for POAG and IOP: a "comprehensive set" based on significant colocalization with at least one of the colocalization methods (CLPP > 0.01 and/or RCP > 0.1) (Supplementary Table 8), and a "high confidence set" based on significance with both methods (CLPP > 0.01 and RCP > 0.1; Table 1

and Supplementary Table 9). Since the number of significantly colocalizing e/sGenes correlated

with the tissue sample size (coefficient of determination R^2=0.72, P=1x10^{-14}, Supplementary Fig.

2), we disregarded the tissue and only considered the QTL type and e/sGene when generating the

list of prioritized causal genes per GWAS locus.

Single nucleus RNA-seq datasets and differential gene expression. We analyzed gene

expression values (log(TPK+1)) from four single nucleus (sn) RNA-seq data sets from the following

glaucoma-relevant regions of the eye: anterior segment, retina, and optic nerve head. All tissue

samples were dissected from non-diseased eye globes from post-mortem donors with no record of

eye disease, and were de-identified. Here is a description of the four datasets:

Anterior segment: Six tissues in the anterior segment, including central cornea,

corneoscleral wedge (CSW), trabecular meshwork (TM), iris, ciliary body (CB) and lens, were

dissected from six donors within 6 hours from death, as described in[28]. To be able to compare

across cell types between tissues in the anterior segment, the snRNA-seq data from cornea, CSW,

CB, iris, and TM were pooled, downsampled to 1000 cells per type in each tissue, and reclustered

yielding 34 clusters[28]. Five clusters were identified for the lens. Differential gene expression

analysis between each cell type and all other cell types was performed using the regression model

in MAST[87] that corrects for the proportion of genes expressed per cell. Only genes expressed in

more than 25% of cells in any cluster and with log$_2$(fold-change) above 0.25 were included in the

analysis.

Retina: Retina samples from the fovea, macula and/or periphery were collected from six

donors within 6 hours from death from the Utah Lions Eye Bank (Supplementary Table 28). The

number of cells from the three retinal regions from each donor is given in Supplementary Table 28.

The fovea (with central macula) and macula samples were collected separately, using a 4 mm and

6 mm disposable biopsy punch, respectively, and were flash-frozen in liquid nitrogen. snRNA-seq

data from RGCs from a few additional donors were added to the data set, given the relevance of

RGCs to glaucoma, though RGCs still only comprised about 1/250 of the total data set. Nuclei were

isolated by pre-chilled fresh-made lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2, 0.02%

NP40). The frozen tissue was triturated to break the tissue structure in lysis buffer and

homogenized with a Wheaton™ Dounce Tissue Grinder. For the nuclei to be enriched, isolated

nuclei were stained with mouse anti-NeuN monoclonal antibody in pre-chilled wash buffer (1% BSA

in PBS, 0.2U/µl RNAse inhibitor) for 30min at 4°C. After being centrifuged at 500g, the pellet was

resuspended in wash buffer and filtered with 40µm Flowmi Cell Strainer. DAPI (4′,6-diamidino-2-

phenylindole, 10 µg/ml) was added before loading the nuclei for fluorescent cytometry sorting.

Stained nuclei were sorted with a FACS Aria II flow sorter (Becton Dickinson, San Jose, CA) (70μm

nozzle). Sorting gates were based on the strengths of DAPI signal and FITC signal. Samples were

sorted at a rate of 50 events per second. Fluorescence detection used a 450-nm/40-nm-band pass

barrier filter for DAPI, and a 530-nm/30-nm-band pass filter for FITC. All single-nuclei RNA

sequencing of the retina samples was performed at the Single Cell Genomics Core at Baylor

College of Medicine. Single-nuclei cDNA library preparation and sequencing were performed

following the manufacturer's protocols (https://www.10xgenomics.com). Single-nuclei suspension

was loaded on a Chromium controller to obtain single-cell GEMS (Gel Beads-In-Emulsions) for the

reaction. The snRNA-seq library was prepared with Chromium Next GEM Single Cell 3' Kit v3.1

(10x Genomics). The library was then sequenced on Illumina NovaSeq 6000

(https://www.illumina.com). Reads from snRNA-seq were demultiplexed and then aligned to the

'Ref_cellranger.hg19.premrna' human reference (from 10x Genomics) using Cell Ranger (version

3.0.2, 10x Genomics). The gene expression matrices were generated by the Cell Ranger pipeline.

For each matrix, genes detected in less than 5 cells were removed; cells with total UMI counts less

than 500 were removed, and the top 5% of cells with the highest mitochondrial gene expression

proportion were removed. We then performed doublet removal on the remaining cells using

DoubletFinder. The gene expression was then normalized by total UMI counts for each cell, scaled

by 10000, and transformed with the natural logarithm. To account for batch effects originating from

sample collection processes, the CarDEC framework[88] was applied with standard parameters. Both

highly variable genes (top 3000) and lowly variable genes were used for building the model, and

donor resources were used as the batch key. The low dimensional embeddings generated were

then used to perform leiden clustering, and major cell types were annotated based on known

marker genes (GNAT1, PDE6A for rod; ARR3, PDE6C for cone; RLBP1, GLUL for MG; C1QA,

C1QB for microglia; GFAP for astrocyte; RPE65, LRAT for RPE). Differential gene expression for

each cell type in the ml_class level used in this study was computed using the Wilcoxon rank sum

test, applied to genes expressed in at least 10% of cells per cell type and with a $\log_2$(fold-change)

above 0.25.

Macula: Macular samples were dissected with 8mm punches from five donors within 4

hours of death at the University of Utah (Supplementary Table 29). For three of the samples, RGCs

were enriched by staining the nuclei with NENU antibody (Millipore Sigma, #FCMAB317PE)

followed by FACS sorting. The macular samples were processed similarly to the optic nerve head

samples below. Differential gene expression for each cell type compared to all other cell types was

computed using the MAST method[87], considering only genes expressed in more than 25% of cells

in any cell type and $\log_2$(fold-change) above 0.25.

Optic nerve head: The optic nerve head, including parapapillary tissues, was dissected
with 4 mm punches from six donors within 4 hours of death at the University of Utah and
Massachusetts General Hospital (Supplementary Table 30). Tissues were frozen and kept at -80C.
For single-nuclei isolation, frozen tissues were homogenized in a dounce homogenizer with 0.1%
NP-40 lysis buffer and passed through a 40-µm cell strainer. The nuclei were then pelleted at 500
rcf over 5 min, resuspended in 2% BSA, and stained with DAPI. ~40K DAPI+ nuclei were sorted
and pelleted at 500 rcf over 5 min. Finally, nuclei were resuspended in 0.04% non-acetylated
BSA/PBS solution and adjusted to a concentration of 1000 nuclei/µL. The integrity of the nuclear
membrane, protrusion of nuclear content, and presence of non-nuclear material were assessed
under a brightfield microscope. Nuclei were then loaded into a 10X Chromium Single Cell Chip with
a targeted recovery of 8000 nuclei. Single nuclei libraries were generated with Chromium 3' V3.1
platform (10X Genomics, Pleasanton, CA) following the manufacturer's protocol. Briefly, single
nuclei were partitioned into Gel-beads-in-EMulsion (GEMs) where nuclear lysis and barcoded
reverse transcription of RNA would take place to yield full-length cDNA; this was followed by
amplification, enzymatic fragmentation, and 5' adaptor and sample index attachment to yield the
final libraries. The single nucleus RNA sequencing of the optic nerve head samples was performed
on NovaSeq machines at a Harvard University facility. snRNA data processing and analyses were
performed similarly to the pipeline used for the anterior segment in van Zyl *et al.*[28]. Differential gene
expression for each cell type compared to all other cell types was computed using the MAST
method[87], considering only genes expressed in more than 25% of cells in any cell type and $\log_2$(fold-
change) above 0.25.

Cell type-specific enrichment of genes that map to GWAS loci for a given complex trait. To
identify ocular cell types that are enriched for cell type-specific expression of genes mapped to
GWAS loci of POAG, IOP and several related traits, we extended a method we recently developed
called ECLIPSER (Enrichment of Causal Loci and Identification of Pathogenic cells in Single Cell
Expression and Regulation data)[36,37], to e/sQTL colocalizing genes. ECLIPSER assesses whether
genes mapped to a set of GWAS loci for a given complex disease or trait are enriched for cell type-
specific expression compared to the cell type specificity of genes mapped to a background (null)
set of GWAS loci associated with hundreds of unrelated traits. The analysis consisted of the
following main steps: **(i) Mapping genes to GWAS loci.** For the POAG and IOP traits, e/sQTL
colocalization was used to prioritize genes in GWAS loci. For the cornea-related traits and VCDR,
genes were mapped to GWAS loci if they were target genes of a GTEx or retina e/sQTL that was
in LD (R^2>0.8) with the GWAS locus (since colocalization analysis for these traits was beyond the

scope of this paper). The genome-wide significant variants associated with the cornea traits were

taken from Open Targets Genetics[89], and for physician and machine learning-based VCDR

measures from the corresponding published GWAS meta-analyses[12,13]. **(ii) Null set of GWAS loci.**

We compiled a null set of GWAS loci, by selecting all genome-wide significant associations for a

range of traits in Open Targets Genetics[89], that were taken from the NHGRI-EBI GWAS catalog

and UK Biobank GWAS studies. We excluded from the null set variants associated with any ocular

trait. **(iii) LD clumping of loci.** We collapsed GWAS variants that were in LD with each other

(R^2>0.8) or that shared a mapped gene into a single locus for the GWAS locus set of each ocular

trait and for the null set, separately, to avoid inflating the cell type enrichment results due to LD[37].

(iv) Cell type specificity locus score. We scored each GWAS locus for the ocular traits and the

null set as the fraction of genes mapped to the locus that demonstrated cell type specificity (defined

here as fold-change > 1.3 and FDR < 0.1). **(v) Assessing cell type-specificity of GWAS locus**

set. We estimated a cell type specificity fold-enrichment and p-value per trait (GWAS locus set),

tissue and cell type combination, compared to the null GWAS locus set, using a Bayesian Fisher's

exact test and the 95th percentile of the null locus scores for the cell type specificity cutoff. The

Bayesian approach enables estimating 95% confidence intervals of the fold-enrichment, including

for traits that have few or no loci that fall above the enrichment cutoff[37]. **(vi) Cell type specific**

disease-contributing genes. Cell type-specific genes mapped to GWAS loci whose score was

equal to or above the 95th percentile enrichment cutoff in significantly enriched cell types ('leading

edge loci'), were proposed to contribute to the given complex trait in the given cell type ('leading

edge genes'). Cell types with a tissue-wide Benjamini-Hochberg FDR equal to or below 0.1,

correcting for the number of cell types tested per tissue, were considered significantly enriched for

genes associated with a given trait.

Enrichment of POAG and IOP associations among e/sQTLs using *QTLEnrich*. To test whether

POAG and IOP trait associations, beyond genome-wide significance, are enriched among eQTLs

and sQTLs and to assess the contribution of e/sQTLs to these traits, we applied *QTLEnrich*[30] to

the POAG and IOP GWAS meta-analyses summary statistics, and eQTLs and sQTLs from the 49

GTEx tissues[29,32] and eQTLs from peripheral retina (EyeGEx[32]). *QTLEnrich* is a rank and

permutation-based method that evaluates the fold-enrichment significance of trait associations

among a set of e/sQTLs in a given tissue, compared to a tissue-specific null distribution of variants

matched on three confounding factors: minor allele frequency (MAF), distance to the target gene's

transcription start site, and local LD[30]. Briefly, fold-enrichment was computed for each trait by

e/sQTL-tissue combination as the fraction of e/sVariants (FDR<0.05) with a GWAS P-value<0.05

compared to expectation, assuming a uniform null distribution. Fold-enrichment was also computed
for $<10^5$ randomly sampled sets of k null variants (non-significant e/sVariants; k = number of
significant e/sVariants in given tissue) matched on the three confounding factors relative to each
significant e/sVariant. Random sampling was applied to decile bins of the confounding factors with
replacement. The null background of variants was defined as all common variants (MAF>1%)
tested for e/sQTL in GTEx or retina excluding the significant e/sVariants (FDR<0.05). The
enrichment p-value was computed as the fraction of up to 10^5 null variant sets whose fold-
enrichment was equal to or higher than that of the significant set of e/sVariants for a given tissue.
To adjust for the potential enrichment of trait associations amongst null variants, an adjusted fold-
enrichment was computed per trait-e/sQTL-tissue combination as the observed fold-enrichment
divided by the median fold-enrichment of 1000 confounder-matched null variant sets. Local LD was
estimated based on the number of LD proxy variants ($R^2 > 0.5$) per variant, using GTEx WGS v8
VCF as the reference panel. For the enrichment analysis only the most significant e/sVariant per
e/sGene (FDR<0.05) in the given tissue was used to prevent inflation of trait association enrichment
due to LD. In cases where the e/sQTL was the most significant e/sVariant for more than one
e/sGene, the smallest distance to TSS was used. Only protein coding and lincRNA genes were
considered in this analysis. Significant tissues were determined based on an Enrichment P-value
that passed Bonferroni correction, correcting for 50 tissues and two QTL types tested ($P<5\times10^{-4}$).
The adjusted fold-enrichment was used to rank the significantly enriched tissues, as this statistic is
not correlated with tissue sample size or number of significant e/sQTLs per tissue[30], as observed
with the colocalization analysis (Supplementary Fig. 2).

For the significant trait-tissue pairs, the fraction and number of e/sVariants proposed to be
associated with POAG or IOP were estimated using an empirically derived, true positive rate (Adj.
π_1) approach implemented in the latest version of *QTLEnrich* (URLs), based on Storey's analytical
π_1[90,91] and an empirical FDR method[90,91]. The adj. π_1 adjusts for enrichment of trait associations
amongst non-significant e/sQTL variants matched on confounding factors. A lambda of 0.8 was
used to estimate the adjusted true negative rate. The estimated number of trait associations
amongst a set of e/sVariants in a given tissue was computed as the adj. π_1 times the number of
e/sQTLs analyzed for that tissue. In few cases, the adj. π_1 can be zero for e/sQTLs that display
significant enrichment of trait associations. This may be caused by deflation of the GWAS p-values
of the e/sQTL set at the higher end of p-values that are used to estimate the true negative rate.
QTLEnrich thus also estimates a lower bound number of trait associations among e/sQTLs with
GWAS P<0.05 that is not affected by this issue (Supplementary Tables 38-39).

Gene set enrichment analysis of POAG and IOP associated genes. We used *GeneEnrich*[29,30] to test whether genes proposed to affect POAG risk or IOP variation in this study cluster in specific biological processes or mouse phenotype ontologies. *GeneEnrich* assesses enrichment of a set of genes of interest in biological pathways or other types of biologically meaningful gene sets, using a hypergeometric distribution and permutation analysis. To account for biases that could arise from the set of genes expressed in a given tissue, an empirical gene set enrichment P-value was computed as the fraction of 1,000 to 100,000 k randomly sampled genes (k = number of significant genes, e.g., colocalizing e/sGenes) from all genes expressed in the given tissue (background set) that have a hypergeometric probability equal to or higher than that of the significant list of genes. *GeneEnrich* has the option to match on expression levels of the significant set of genes when randomly sampling genes from the background set, to ensure that significant gene set enrichment is not driven by expression levels in the particular tissue. Given the high LD in the HLA region on chromosome 6 (chr6:28510120-33480577) we removed all genes in this region from the gene set enrichment analysis, unless noted otherwise.

We applied *GeneEnrich* to three groups of POAG and IOP associated genes: (i) All 228, 118, and 279 unique target genes of eQTLs and sQTLs that colocalized with POAG CA, POAG EUR, and IOP GWAS loci, respectively. Given that the colocalizing e/sQTLs were derived from the different GTEx tissues and retina, we used all genes expressed in any of the 49 GTEx tissues and retina as the background set of genes, and did not correct for expression levels given the differences in expression levels between tissues. (ii) Sets of POAG and IOP colocalizing genes that were enriched in specific cell types in the eye tissues based on ECLIPSER analysis (tissue-wide FDR ≤ 0.1). For the background sets of genes, we chose all genes expressed in the GTEx or retina tissue that was relevant for the enriched cell type (e.g., Brain for Optic nerve head; full list in Supplementary Table 32). Given that the expression levels in a tissue may not fully reflect the expression levels in the particular cell type, we did not correct for expression levels in the gene set enrichment analysis of the cell type-specific gene sets. (iii) Target genes of e/sQTLs (FDR<0.05) with POAG or IOP GWAS P-value below 0.05 in tissues that were enriched for trait associations based on *QTLEnrich*. Given that e/sQTLs in most tissues displayed significant enrichment, a select set of QTL/tissue-trait pairs was chosen for gene set enrichment analysis based on the tissue having a top ranked adjusted fold-enrichment and consisting of cell types that may be relevant to glaucoma pathophysiology, such as cells cultured fibroblasts, brain, and artery. The background sets of genes were defined as all genes expressed in the given tissue whose most significant e/sVariant had a GWAS P-value above 0.05. Expression levels were adjusted for in the permutation analysis.

We applied *GeneEnrich* to over 11,000 gene sets from four databases downloaded from
MSigDB (URLs): Gene Ontology (GO) with three domains: biological processes, molecular
function, and cellular components; Reactome; Kyoto Encyclopedia of Genes and Genomes
(KEGG); and mouse phenotype ontology gene sets from the Mouse Genome Informatics (MGI).
Only gene sets with 10 to 1000 genes were tested. Only genes that were found in the given
database were included in the gene set enrichment analysis. Statistical significance was
determined using a Benjamini Hochberg false discovery rate (FDR) below 0.1 per database, given
extensive gene set overlap between databases. Gene sets with empirical gene set enrichment
below 0.05 were considered nominally significant.

1028

Conditional analysis of *MYOC* POAG locus. Given our finding of significant colocalization of a
PIGC sQTL with the POAG cross-ancestry association signal in the GWAS locus rs74315329
(chr1:171636338:G:A, MAF=0.0026, odds ratio=5.47) whose lead variant is a nonsense mutation
in the *MYOC* gene, we tested whether there was a secondary independent signal in this locus that
might colocalize with the *PIGC* sQTL. We performed association testing on all variants on
chromosome 1 conditioning on rs74315329, the lead POAG GWAS variant in the locus by applying
the tool COJO (URLs) to the POAG trans-ancestry GWAS meta-analysis summary statistics on
chromosome 1. To maintain the *MYOC* lead variant in the initial association testing we filtered out
variants with MAF<0.0001. The effective sample size of the POAG cross-ancestry GWAS was
computed based on the equation: $4/[(1/N_{cases})+(1/N_{controls})]$[92], which yielded N=124,531 for the
POAG GWAS cross-ancestry meta-analysis[8]. The variant allele frequencies required as input to
COJO, we computed the minor allele frequencies per variant using the European, African and East
Asian samples in 1000 Genomes Project, as the POAG GWAS meta-analysis is comprised of three
ancestral groups. eCAVIAR and *enloc* were applied to the residual statistics in the *MOYC* locus
from the conditional analysis and all overlapping e/sQTLs from the GTEx tissues and retina. To
remove potential false positives, we filtered out variant, gene, tissue, trait combinations if the
e/sVariant with a significant colocalization result had a GWAS p-value above 2×10^{-5} or an e/sQTL
p-value above 1×10^{-4} and/or an FDR above 0.05 (FALSE in column
'Pass_QC_QTL_FDR05_P1E04_GWAS_P2E05' in Supplementary Tables 19 and 21). We used a
slightly more lenient GWAS p-value cutoff for the conditional analysis ($P<2\times10^{-5}$ compared to
$P<1\times10^{-5}$ used for the original GWAS summary statistics) given the reduced association power of
conditional analysis.

1051

1052   **Acknowledgements**

We thank William Wen for helpful discussions on the interpretation of the colocalization results. We thank members of the Segrè lab for valuable comments and feedback. This work was funded by NIH/NEI R01 EY031424-01 (AVS, ARH, JR, PAM), NIH/NEI P30 EY014104 (JLW, AVS), NIH/NEI EY032559-01 (JLW, AVS), and the Chan Zuckerberg Initiative (CZI) Seed Network for the Human Cell Atlas awards CZF2019-002459 and CZF2019-002425. XJ is supported by the University of Edinburgh and University of Helsinki joint PhD studentship program in Human Genomics. VV is supported by an MRC University Unit Programme grant (MC_UU_00007/10) (QTL in Health and Disease). All GTEx protected data are available through the database of Genotypes and Phenotypes (dbGaP) (accession no. phs000424.v8).

URLs

GTEx: https://gtexportal.org/home/datasets

EyeGEx: https://gtexportal.org/home/datasets

PLINK: https://www.cog-genomics.org/plink/

eCAVIAR: https://github.com/fhormoz/caviar

fastEnloc: https://github.com/xqwen/fastenloc

DAP-G: https://github.com/xqwen/dap/tree/master/dap_src

COJO: https://yanglab.westlake.edu.cn/software/gcta/

ECLIPSER: https://github.com/segrelabgenomics/ECLIPSER

QTLEnrich: https://github.com/segrelabgenomics/QTLEnrich

GeneEnrich: https://www.asegrelab.org/software

genomAD: https://gnomad.broadinstitute.org/

MSigDB: http://www.gsea-msigdb.org/gsea/msigdb/collections.jsp

QMplot: https://github.com/ShujiaHuang/qmplot

LocusCompare: https://github.com/boxiangliu/locuscomparer

Figure 1

Figure 1. Analysis workflow from POAG and IOP GWAS to causal regulatory mechanisms, genes, pathways, and cell types. a, Putative causal genes were prioritized per known POAG and IOP GWAS locus by applying two colocalization methods to all e/sQTLs from 49 GTEx tissues and retina eQTLs that overlapped each locus. A Manhattan plot of the POAG cross-ancestry GWAS meta-analysis[8] was plotted with QMplot (URLs). **b**, All target genes of significantly colocalizing e/sQTLs per trait were tested for enrichment in signaling and metabolic pathways (Reactome, KEGG), gene ontologies and mouse phenotype ontologies using *GeneEnrich*. **c**, Significantly colocalizing e/sGenes were tested for enrichment in specific cell types in single nucleus RNA-seq data of glaucoma-relevant eye tissues, using ECLIPSER. A gene was considered significant with cell type fold-change >1.3 and FDR<0.1 per tissue. Cell type specificity significance per GWAS locus set for a given trait was assessed against a null distribution of GWAS loci associated with unrelated, non-ocular traits, using a Bayesian Fisher's exact test. Genes mapped to GWAS loci with a cell type specificity score above the 95th percentile of null locus scores were proposed as contributing to the trait in the enriched cell type. **d**, All POAG and IOP associations genome-wide, beyond the known GWAS loci, were tested for enrichment among e/sQTLs in GTEx tissues and retina compared to permuted null sets of variants matched on confounding factors, using *QTLEnrich*. If enrichment was found, the number of e/sQTLs in a given tissue likely to be true trait associations was estimated based on an empirically derived, true positive rate (π_1) approach.

Figure 2. Summary of colocalization analysis of POAG and IOP GWAS loci with eQTLs and sQTLs. a, Histogram of percent of GWAS loci with at least one colocalizing e/sQTL (eCAVIAR CLPP > 0.01 and/or *enloc* RCP > 0.1) across the three traits (POAG Cross-ancestry, POAG European (EUR) ancestry subset, and IOP European ancestry). Numbers above the bars represent the number of loci with at least one colocalizing e/sQTL. Red, dark blue, and light blue bars indicate percentage of loci with at least one colocalizing eGene, sGene, or both, respectively. **b**, Scatter plot comparing unique number of e/sGenes per locus that significantly colocalized per locus versus unique number of e/sGenes tested per locus. Points are color-coded by number of GWAS loci. The black line represents the diagonal. **c**, Violin plots showing distribution of the unique number of colocalizing eGenes (red), sGenes (dark blue), or both (light blue) per locus for the three GWAS tested. The center line in the box plots contained within each violin plot shows the median and the box edges depict the interquartile range. **d**, Stacked histogram showing the number of colocalizing e/sGenes per gene biotype for each GWAS. Protein coding (light blue), lincRNA (brown), antisense (gray), pseudogenes (yellow), and other (dark blue).

Figure 3

Top POAG cross-ancestry GWAS loci

Figure 3. Colocalizing e/sQTLs in GTEx tissues and retina with top POAG GWAS loci. Genes with at least one significant colocalization result are shown for e/sQTLs tested across 49 GTEx tissues and peripheral retina for the top 21 POAG cross-ancestry GWAS loci. GWAS loci were ordered by absolute value of their effect size. Within each locus, genes were ordered based on their chromosome position. Bubble size is proportional to the maximum colocalization posterior probability of all e/sVariants tested for the given gene, QTL type and tissue combination. Points are color-coded by direction of effect (blue if increased expression or splicing increases POAG risk or vice versa; red if increased expression or splicing decreases POAG risk or vice versa). Shape of points indicates colocalization method used: circle (eCAVIAR), triangle (*enloc*), and square (tested in both methods; results shown for method with maximum posterior probability). Gray or black border denotes variant-gene-tissue-QTL combination that passed QC filtering (Methods) and a colocalization posterior probability cutoff above 0.01/0.1 (CLPP/RCP) or 0.5 (higher confidence), respectively. White or black asterisk in the square indicates whether the second method tested passed a posterior probability cutoff 0.01/0.1 (CLPP/RCP) or 0.5, respectively.

Figure 4

Figure 4. Examples of colocalizing e/sQTLs with top POAG and IOP GWAS loci. a, Colocalization results for all e/sGenes tested in the POAG cross-ancestry rs2790053 locus LD interval that had at least one significant eQTL or sQTL result across 49 GTEx tissues and peripheral retina based on eCAVIAR or *enloc*. Genes were ordered by chromosome position. Size of points is proportional to the maximum colocalization posterior probability of all e/sVariants tested for the given gene, QTL type and tissue combination. Points are color-coded by direction of effect (blue if increased expression or splicing increases POAG risk or vice versa; red if increased expression or splicing decreases POAG risk or vice versa). Shape of points indicates colocalization method used: circle (eCAVIAR), triangle (*enloc*), and square (tested in both methods; results shown for method with maximum posterior probability). Gray or black border denote variant-gene-tissue-QTL combination that passed QC filtering (Methods) and a colocalization posterior probability cutoff above 0.01/0.1 (CLPP/RCP) or 0.5, respectively. White or black asterisk in the square indicates whether the second method tested passed a posterior probability cutoff of 0.01/0.1 (CLPP/RCP) or 0.5, respectively. **b**, LocusZoom[83] plot for *TMCO1* sQTL -$\log_{10}$(P-value) in GTEx Cells Cultured fibroblasts in the POAG cross-ancestry GWAS variant rs2790053 (chr1_165768467_C_G_b38) LD interval. Points are color-coded by LD (r^2) relative to the lead GWAS variant, chr1_165768467_C_G_b38. **c,d** LocusCompare plot of -$\log_{10}$(P-value) of the POAG cross-ancestry GWAS meta-analysis versus the -$\log_{10}$(P-value) of the Cells Cultured fibroblast sQTL or eQTL acting on *TMCO1* (**c**) or *RP11-466F5.8* (**d**)*,* respectively. Points are color-coded based on LD (r^2) relative to the variant with the highest eCAVIAR colocalization posterior probability (CLPP). **e,** Violin plot of normalized intron-excision ratio for chr1:165768269-165768482 computed with Leafcutter[82] for *TMCO1* in Cells Cultured fibroblasts as a function of the genotype of the sVariant chr1_165817713_G_A_b38 (rs143863391) with the highest CLPP (0.92) for this sQTL and the POAG cross-ancestry GWAS locus rs2790053. The effect size of the sQTL relative to the alternative allele (*beta* = -0.43) is in opposite direction relative to the GWAS variant (*beta* = 0.25), suggesting that decreased splicing between chr1:165768269-165768482 increases POAG risk. **f,** Gene model for *TMCO1* in GTEx Cells Cultured fibroblasts on the negative strand showing all the intron excision splicing events detected with Leafcutter in *TMCO1*. A zoom in of the splicing event (chr1:165768269-165768482; red), an alternative splice donor site on exon 4 (red versus blue or green), associated with an sVariant (chr1_165817713_G_A_b38) that colocalized with POAG risk is shown*.* A longer exon 4 in *TMCO1* is associated with decreased risk of POAG. **g,** *TMCO1* gene model and transcripts expressed in Cells Cultured fibroblasts taken from the GTEx portal (URLs). In the gene model, exon boxes are color-coded by exon read counts per base (blue) and lines connecting exons by exon-exon junction read counts (red). All splicing events observed in the tissue are shown, including the alternative splice event between exon 4 and exon 5 whose genetic regulation colocalized with POAG (**c**)*.* Below the gene model, transcript expression in Cells Cultured fibroblasts in Transcripts per Million (TPM), computed with RSEM[93], is shown in descending order.

Figure 5

Figure 5. Cell type enrichment of e/sQTL-mapped genes for POAG, IOP and related trait loci in the anterior segment of the eye. a, Significance (circle size, -log10(P-value)) and fold-enrichment (circle color) of the cell type specificity of GWAS locus sets for POAG cross-ancestry, POAR European subset, IOP, central cornea thickness, corneal hysteresis, physician-defined Vertical-cup-to-disc ratio (VCDR), and machine learning (ML)-defined VCDR (VCDR_ML_Alipanahi) are shown for each of the 39 cell types found in six tissues in the anterior segment of the eye[28]. Traits (rows) and cell types (columns) were clustered based on hierarchical clustering of the euclidean distance between GWAS locus set cell type-specificity enrichment scores. Red rings: experiment-wide significant (Benjamini Hochberg (BH) FDR<0.1); Yellow rings: tissue-wide significant (BH FDR<0.1); Gray rings: nominal significant (P<0.05). **b,d,e** Cell type specificity fold-enrichment (x-axis) in the different anterior segment cell types ranked in descending order for the POAG European subset (**b**), POAG cross-ancestry (**d**), and IOP (**e**) GWAS locus sets. Error bars: 95% confidence intervals. Red: tissue-wide significant (FDR<0.1); Gray: nominal significant (P<0.05); Blue: non-significant (P≥0.05). **c,h,** Differential expression (log$_2$(Fold-change), y axis) in the most strongly enriched cell type compared to all other cell types is shown for the set of genes (x axis) driving the enrichment signal of the POAG European GWAS loci in ciliary fibroblasts (**c**) and the IOP GWAS loci in pericytes (cluster 2) (**h**). Vertical dashed line represents log$_2$(Fold-change) of 0.375 (FC=1.3) and FDR<0.1 that was used as the cell type-specificity enrichment cutoff. Asterisks denote genes in IOP loci not associated with POAG risk (**h**). **f-g,** Heatmap of fraction of genes that overlap between the e/sGenes driving the enrichment signal for top ranked cell types (P<0.05) in the anterior segment for POAG cross-ancestry (CA) (**f**) and IOP (**g**) GWAS loci. Numbers refer to the fraction of e/sGenes driving the cell type enrichment on each row that overlaps with the genes driving the cell type enrichment on the corresponding column. Hierarchical clustering was performed on both rows and columns using the euclidean distance between fractions. Red asterisks: tissue-wide BH FDR<0.1. **i,** Bubble map displaying the expression of the e/sGenes driving the IOP enrichment in pericytes across all cell types in the anterior segment. The colorbar represents gene expression z-scores computed by comparing each gene's average expression in a given cell type to its per cell type average expression across all types divided by the standard deviation of all cell type expression averages. Bubble size is proportional to the percentage of cells expressing the given gene (log(TPK+1)>1). Cell type abbreviations are described in Supplementary Table 31.

Figure 6

Figure 6. Cell type enrichment of e/sQTL-mapped genes for POAG, IOP and related trait loci in optic nerve head and surrounding retina. a, Significance (circle size, -log10(P-value)) and fold-enrichment (circle color) of the cell type specificity of GWAS locus sets for POAG cross-ancestry, POAR European subset, IOP, central cornea thickness, corneal hysteresis, and physician (VCDR) and machine learning (ML)-defined VCDR (VCDR_ML_Alipanahi) are shown for each of the 17 cell types found in optic nerve head (ONH) and surrounding retina. Traits (rows) and cell types (columns) were clustered based on hierarchical clustering of the euclidean distance between GWAS locus set cell type-specificity enrichment scores. Red rings: experiment-wide significant (Benjamini Hochberg (BH) FDR<0.1); Yellow rings: tissue-wide significant (BH FDR<0.1); Gray rings: nominal significant (P<0.05). **b-d,** Cell type specificity fold-enrichment (x-axis) in the ONH cell types ranked in descending order for the POAG cross-ancestry (**b**), POAG European (**c**), and IOP (**d**) GWAS locus sets. **e,** Differential expression ($\log_2$(Fold-change)) in astrocytes, the most strongly enriched cell type for POAG cross-ancestry GWAS loci in the ONH, compared to all other cell types is shown for the set of genes driving the POAG enrichment signal in astrocytes. Vertical dashed line represents $\log_2$(Fold-change) of 0.375 (FC=1.3) and FDR<0.1 that was used as the cell type-specificity enrichment cutoff. **f,** The expression profile of the e/sGenes driving the POAG cross-ancestry enrichment signal in astrocytes is shown across all cell types in the optic nerve head (ONH). Color represents z-scores computed by comparing each gene's average expression in a given cell type to the average expression across cell types divided by its standard deviation of all cell type expression averages. Bubble size is proportional to the percentage of cells expressing the gene (log(TPK+1)>1). **g,** LocusCompare plot of $-\log_{10}$ (P-value) of the POAG cross-ancestry GWAS meta-analysis relative to $-\log_{10}$(P-value) of a retina eQTL acting on *DGKG* that significantly colocalized with the POAG GWAS locus rs56233426 (chr3_186411027_G_A). *DGKG* is the strongest astrocyte-specific gene driving the cell type enrichment signal for POAG loci. Points are color-coded based on LD (r^2) relative to the eVariant with the highest colocalization posterior probability (CLPP=0.93). The red arrow is pointing to the lead POAG GWAS variant. MG, Müller Glia; BC, bipolar cells; vEndo, vascular endothelium; Oligo, oligodendrocytes; RGC, retinal ganglion cells; AC, amacrine cells; Mø, macrophages; HC, horizontal cells; RPE, retinal pigment epithelium.

Figure 7

Figure 7. e/sQTLs enriched for hundreds of new POAG and IOP associations. a-c, Boxplots showing the distributions of three *QTLEnrich* summary statistics for POAG Cross-ancestry GWAS, POAG European (EUR) ancestry GWAS, and IOP GWAS for the significant tissue-trait pairs that passed Bonferroni correction for testing enrichment of trait associations amongst eQTLs (dark gray) and sQTLs (light gray) from 49 GTEx tissues and retina eQTLs: adjusted fold-enrichment (**a**), estimated true positive rate of trait associations among e/sQTLs (Adjusted π_1) (**b**), and estimated number of trait associations based on adjusted π_1 (**c**). The center lines in the box plots depict the median value and the box edges the interquartile range. **d**, **f** Quantile-quantile (Q-Q) plot of POAG Cross-ancestry (**d**) and IOP (**f**) GWAS -$\log_{10}$ (P-value) compared to expectation for the best eQTL per eGene set (eVariants with FDR < 0.05) of the top enriched tissues based on adjusted fold-enrichment (colored lines), compared to all variants in the GWAS (black points). Gray line represents the diagonal. **e**, Q-Q plot of POAG Cross-ancestry GWAS -$\log_{10}$(P-value) for the significant best eQTL per eGene set (FDR < 0.05) in one of the top enriched tissues, Cells - Cultured fibroblasts (red points), compared to GWAS p-values of 1,000 confounder-matched null variant sets (light gray) generated by *QTLEnrich*. **g**, Forest plots (left panel) and barplots (right panel) of all tissues whose eQTLs were significantly enriched (Bonferroni correction) for POAG Cross-ancestry GWAS associations based on *QTLEnrich*. Points indicate the adjusted fold-enrichment scaled by -log10(Enrichment P-value) and the lines represent 95% confidence intervals. Barplots show estimated number of e/sQTLs that are likely true trait associations per enriched tissue using an adjusted true positive rate, π_1 approach. The lack of estimated number of POAG associations among prostate eQTLs is likely due to deflation of the GWAS p-values of the prostate eQTL set (see Methods).

1102   **Table 1. List of high confidence colocalizing e/sGenes with POAG and IOP GWAS loci.**

1103

GWAS locus	RS ID	GWAS effect (OR or beta)	# e/sGenes tested per locus	# significantly colocalizing e/sGenes with eCAVIAR or enloc	Colocalizing e/sGenes with eCAVIAR and enloc	Significantly colocalizing Retina eQTL	Nearest Gene	Significant in GWAS:	
POAG cross-ancestry GWAS								**IOP**	**POAG European**
chr1:171636338:G:A	rs74315329	5.46957	24	1	PIGC (s)	-	-	-	-
chr1:165768467:G:C	rs2790053	1.35026	13	2	TMCO1 (e,s)	-	+	TMCO1	TMCO1
chr9:22051671:G:C	rs944801	1.2663	26	3	CDKN2B-AS1 (s)	-	+	-	CDKN2B-AS1
chr4:7902636:G:A	rs938604	0.866407	27	2	AFAP1 (e)	-	+	AFAP1	-
chr17:10127866:G:A	rs9913911	1.14912	30	1	GAS7 (e)	-	+	GAS7	GAS7
chr9:126628521:C:T	rs3829849	0.87529	11	4	LMX1B (e)	-	+	LMX1B	LMX1B
chr7:116522252:T:A	rs10257125	0.890921	18	2	CAV2 (e,s)	-	-	CAV2	CAV2
chr11:86657064:C:T	rs10792871	1.12142	15	4	PRSS23 (e), ME3 (e)	-	+	PRSS23, ME3	PRSS23, ME3
chr9:133255801:C:T	rs8176749	1.10186	18	1	ABO (e)	-	+	ABO	-
chr15:73928957:C:T	rs1550437	0.913657	72	2	LOXL1 (e,s)	-	+	-	LOXL1
chr3:188349165:G:T	rs6787621	0.92626	7	1	LPP (e,s)	-	+	LPP	-
chr22:28712241:G:A	rs5752776	0.926631	27	5	TTC28 (e), CHEK2 (e)	-	+	-	TTC28, CHEK2
chr2:12811195:C:T	rs12623251	0.932021	11	1	TRIB2 (e)	-	+	-	TRIB2
chr15:57261634:T:A	rs2431023	1.07026	16	2	ZNF280D (e), TCF12 (e)	-	+	-	ZNF280D, TCF12
chr11:130412183:C:T	rs2875238	0.935289	7	2	RP11-121M22.1 (e,s), ADAMTS8 (e)	-	+	-	-
chr1:53658200:G:T	rs941125	1.0646	13	2	GLIS1 (e)	-	+	-	-
chr7:134835770:C:A	rs10237321	0.94535	29	1	CALD1 (e)	-	+	-	-
chr6:134051012:G:C	rs2811688	0.946296	3	3	SLC2A12 (e), TBPL1 (e)	SLC2A12	+	-	SLC2A12, TBPL1
IOP GWAS								**POAG European**	**POAG cross-ancestry**
chr1:165715441:C:T	rs116089225	-0.744	29	3	TMCO1 (e)	-	+	TMCO1	TMCO1
chr14:74498200:C:T	rs74384554	0.417	70	4	NPC2 (e)	NPC2	-	-	NPC2
chr1:165745179:C:T	rs10918274	0.377	14	3	TMCO1 (e)	-	+	TMCO1	TMCO1
chr17:10127866:G:A	rs9913911	0.231	3	1	GAS7 (e)	-	+	GAS7	GAS7
chr7:116511284:C:T	rs10281637	-0.225	13	3	CAV2 (e), CAV1 (e)	-	+	CAV2	CAV2
chr11:120422429:G:A	rs11217863	-0.224	17	2	ARHGEF12 (e,s)	-	+	ARHGEF12	ARHGEF12
chr2:218937686:C:A	rs73103335	0.206	11	2	LYPLAL1-AS1 (e,s)	-	+	-	-
chr5:108710999:G:A	rs73220177	0.165	9	2	LINC01023 (e)	-	-	-	-
chr22:19854787:G:A	rs17534001	0.16	26	4	TXNRD2 (e,s)	-	+	TXNRD2	TXNRD2
chr6:170146547:G:T	rs59020521	-0.148	18	2	RP11-302L19.3 (e)	-	-	-	RP11-302L19.3
chr2:29224336:C:A	rs9608740	-0.141	40	3	EMID1 (e,s)	-	+	EMID1	-
chr2:238402728:C:T	rs57435966	0.132	25	3	TRAF3IP1 (e)	-	+	-	-
chr11:16989629:C:A	rs4141194	-0.131	18	5	NCR1LG1 (e), KCNJ11 (e,s), NUCB2 (s)	NCR3LG1	-	-	NUCB2
chr11:86699199:C:T	rs2433414	-0.128	22	6	ME3 (e)	-	+	ME3	ME3
chr11:47253513:G:A	rs10838681	-0.124	56	12	PTPRJ (e)	-	-	-	-
chr3:50162314:G:A	rs11710277	-0.12	117	14	LSMEM2 (e)	-	-	-	-
chr15:61659036:C:T	rs4775427	-0.111	7	5	RP11-507B12.1 (e), RP11-507B12.2 (e), RP11-162I7.1 (e)	-	-	RP11-507B12.1, RP11-507B12.2, RP11-162I7.1	RP11-507B12.1, RP11-507B12.2, RP11-162I7.1
chr14:52920118:G:C	rs8009633	0.11	12	2	FERMT2 (e,s)	-	+	-	-
chr2:101031432:G:A	rs55771809	0.109	17	3	TBC1D8 (s)	TBC1D8	+	-	-
chr7:116171382:C:A	rs2896175	0.108	12	4	TES (e)	-	-	-	-
chr16:89752083:C:T	rs3743860	0.102	57	14	ZNF276 (e,s), SPIRE2 (e), FANCA (e,s), DPEP1 (e), VPS9D1 (e)	-	+	-	-
chr11:78374959:C:T	rs10793308	0.098	25	4	NARS2 (e,s), USP35 (e)	-	-	-	-
chr11:86789199:C:T	rs11606902	-0.098	12	4	PRSS23 (e), ME3 (e)	PRSS23	+	PRSS23, ME3	PRSS23, ME3
chr1:112639117:G:C	rs61818802	-0.097	14	4	MOV10 (e), RHOC (e)	-	-	-	MOV10
chr3:50143702:G:T	rs2526385	0.096	116	16	LSMEM2 (e)	-	-	-	-
chr22:37788844:C:T	rs6000889	0.094	47	10	GCAT (e,s), ANKRD54 (e)	-	-	-	GCAT
chr7:11644065:C:T	rs1635182	-0.094	4	1	THSD7A (e)	-	+	-	THSD7A
chr3:188343926:C:T	rs4132172	0.093	4	2	LPP (e,s)	-	+	-	LPP
chr17:46758936:C:T	rs9912530	0.091	58	14	WNT3 (e)	-	+	WNT3	-
chr1:37627051:C:T	rs4074961	-0.089	17	5	GNL2 (e,s), MEAF6 (e), DNALI1 (s)	-	-	GNL2, MEAF6, DNALI1	-
chr10:80411803:C:T	rs6585986	-0.084	37	4	TSPAN14 (s), ANXA11 (e)	-	-	-	-
chr13:75683130:G:C	rs9544022	-0.081	9	2	LMO7 (s)	-	+	LMO7	-
chr2:217802649:T:A	rs3791979	-0.081	9	2	TNS1 (e,s)	-	+	-	-
chr11:817786:C:T	rs10902223	0.079	49	18	PIDD1, CRACR2B, PNPLA2, CHID1	-	-	-	-
chr10:92670768:G:A	rs9419741	-0.077	19	4	HHEX (e)	-	+	-	-
chr1:31726197:G:C	rs945211	-0.073	28	5	COL16A1 (e,s)	-	-	-	-
chr6:39895441:G:A	rs3004063	0.071	9	3	MOCS1 (e), RP11-61I13.3 (e,s),	-	+	-	-
chr17:49264218:C:T	rs9899665	-0.069	31	2	GNGT2 (e)	-	-	-	-

1104

References

1. Tham, Y.-C. *et al.* Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* **121**, 2081–2090 (2014).

2. Weinreb, R. N. *et al.* Primary open-angle glaucoma. *Nat Rev Dis Primers* **2**, 16067 (2016).

3. Leske, M. C. *et al.* Predictors of long-term progression in the early manifest glaucoma trial. *Ophthalmology* **114**, 1965–1972 (2007).

4. Kwon, Y. H., Fingert, J. H., Kuehn, M. H. & Alward, W. L. M. Primary open-angle glaucoma. *N. Engl. J. Med.* **360**, 1113–1124 (2009).

5. Kim, J. *et al.* Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma. *J. Clin. Invest.* **127**, 3877–3896 (2017).

6. Costagliola, C. *et al.* How many aqueous humor outflow pathways are there? *Surv. Ophthalmol.* **65**, 144–170 (2020).

7. Anderson, D. R., Drance, S. M., Schulzer, M. & Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. *Ophthalmology* **108**, 247–253 (2001).

8. Gharahkhani, P. *et al.* Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. *Nat. Commun.* **12**, 1258 (2021).

9. Khawaja, A. P. *et al.* Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. *Nature Genetics* vol. 50 778–782 (2018).

10. MacGregor, S. *et al.* Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. *Nature Genetics* vol. 50 1067–1071 (2018).

11. Gao, X. R. *et al.* Genome-wide association analyses identify new loci influencing intraocular pressure. *Human Molecular Genetics* vol. 27 2205–2213 (2018).

12. Alipanahi, B. *et al.* Large-scale machine-learning-based phenotyping significantly improves genomic discovery for optic nerve head morphology. *Am. J. Hum. Genet.* **108**, 1217–1230 (2021).

13. Springelkamp, H. *et al.* New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics. *Hum. Mol. Genet.* **26**, 438–453 (2017).

14. Lu, Y. *et al.* Common genetic variants near the Brittle Cornea Syndrome locus ZNF469 influence the blinding disease risk factor central corneal thickness. *PLoS Genet.* **6**, e1000947 (2010).

15. Vitart, V. *et al.* New loci associated with central cornea thickness include COL5A1, AKAP13 and AVGR8. *Hum. Mol. Genet.* **19**, 4304–4311 (2010).

16.   Hoehn, R. *et al.* Population-based meta-analysis in Caucasians confirms association with

COL5A1 and ZNF469 but not COL8A2 with central corneal thickness. *Hum. Genet.* **131**, 1783–

1793 (2012).

17.   Gao, X. *et al.* A genome-wide association study of central corneal thickness in Latinos.

Invest. Ophthalmol. Vis. Sci. **54**, 2435–2443 (2013).

18.   Iglesias, A. I. *et al.* Cross-ancestry genome-wide association analysis of corneal thickness

strengthens link between complex and Mendelian eye diseases. *Nat. Commun.* **9**, 1864 (2018).

19.   Gao, X. *et al.* Genome-wide association study identifies WNT7B as a novel locus for

central corneal thickness in Latinos. *Hum. Mol. Genet.* **25**, 5035–5045 (2016).

20.   Fan, B. J. *et al.* Family-Based Genome-Wide Association Study of South Indian Pedigrees

Supports WNT7B as a Central Corneal Thickness Locus. *Invest. Ophthalmol. Vis. Sci.* **59**, 2495–

2502 (2018).

21.   Ivarsdottir, E. V. *et al.* Sequence variation at ANAPC1 accounts for 24% of the variability

in corneal endothelial cell density. *Nat. Commun.* **10**, 1284 (2019).

22.   Simcoe, M. J., Khawaja, A. P., Hysi, P. G., Hammond, C. J. & UK Biobank Eye and Vision

Consortium. Genome-wide association study of corneal biomechanical properties identifies over

200 loci providing insight into the genetic etiology of ocular diseases. *Hum. Mol. Genet.* **29**, 3154–

3164 (2020).

23.   Han, X. *et al.* Automated AI labeling of optic nerve head enables insights into cross-

ancestry glaucoma risk and genetic discovery in >280,000 images from UKB and CLSA. *Am. J.*

Hum. Genet. **108**, 1204–1216 (2021).

24.   Yan, W. *et al.* Cell Atlas of The Human Fovea and Peripheral Retina. *Sci. Rep.* **10**, 9802

(2020).

25.   Dharmat, R., Kim, S., Li, Y. & Chen, R. Single-Cell Capture, RNA-seq, and Transcriptome

Analysis from the Neural Retina. *Methods Mol. Biol.* **2092**, 159–186 (2020).

26.   van Zyl, T. *et al.* Cell atlas of aqueous humor outflow pathways in eyes of humans and

four model species provides insight into glaucoma pathogenesis. *Proc. Natl. Acad. Sci. U. S. A.*

117, 10339–10349 (2020).

27.   Patel, G. *et al.* Molecular taxonomy of human ocular outflow tissues defined by single-cell

transcriptomics. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 12856–12867 (2020).

28.   van Zyl Wenjun Yan Alexi McAdams Aboozar Monavarfeshani Gregory S. Hageman

Joshua R. Sanes, T. Cell atlas of the human ocular anterior segment: Tissue-specific and shared

cell types. *bioRxiv* (2022) doi:10.1101/2022.01.19.476971.

29.   GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
human tissues. *Science* **369**, 1318–1330 (2020).

30.   Gamazon, E. R. *et al.* Using an atlas of gene regulation across 44 human tissues to
inform complex disease- and trait-associated variation. *Nat. Genet.* **50**, 956–967 (2018).

31.   Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies
disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).

32.   Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated
with age-related macular degeneration. *Nat. Genet.* **51**, 606–610 (2019).

33.   Strunz, T. *et al.* A mega-analysis of expression quantitative trait loci in retinal tissue. *PLoS*
Genet. **16**, e1008934 (2020).

34.   Hormozdiari, F. *et al.* Colocalization of GWAS and eQTL Signals Detects Target Genes.
Am. J. Hum. Genet. **99**, 1245–1260 (2016).

35.   Wen, X., Pique-Regi, R. & Luca, F. Integrating molecular QTL data into genome-wide
genetic association analysis: Probabilistic assessment of enrichment and colocalization. *PLoS*
Genet. **13**, e1006646 (2017).

36.   Eraslan, G. *et al.* Single-nucleus cross-tissue molecular reference maps to decipher
disease gene function. *bioRxiv* 2021.07.19.452954 (2021) doi:10.1101/2021.07.19.452954.

37.   Rouhana, J., J. Wang, G. Eraslan, S. Anand, A. Hamel, B. Cole, A. Regev, F. Aguet, K.
Ardlie, and A. V. Segrè. ECLIPSER: identifying causal cell types and genes for complex traits
through single cell enrichment of e/sQTL-mapped genes in GWAS loci. *BioRxiv* (2021)
doi:10.1101/2021.11.24.469720.

38.   Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at
GWAS loci. *Genome Biol.* **22**, 49 (2021).

39.   Wiggs, J. L. *et al.* Common variants at 9p21 and 8q22 are associated with increased
susceptibility to optic nerve degeneration in glaucoma. *PLoS Genet.* **8**, e1002654 (2012).

40.   Collantes, E. R. A. *et al.* EFEMP1 rare variants cause familial juvenile-onset open-angle
glaucoma. *Hum. Mutat.* **43**, 240–252 (2022).

41.   van Zyl Gregory Hagemna Joshua R. Sanes, A. M. W. Y. T. Cell atlas of the human optic
nerve and optic nerve head. *bioRxiv (in preparation)* (2022).

42.   Lewczuk, K., Jabłońska, J., Konopińska, J., Mariak, Z. & Rękas, M. Schlemm's canal: the
outflow 'vessel'. *Acta Ophthalmol.* (2021) doi:10.1111/aos.15027.

43.   GTEx Consortium *et al.* Genetic effects on gene expression across human tissues. *Nature*
550, 204–213 (2017).

44.   Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.
N. Engl. J. Med. **373**, 895–907 (2015).

45.   Nasser, J. *et al.* Genome-wide enhancer maps link risk variants to disease genes. *Nature*
593, 238–243 (2021).

46.   Cao, J. *et al.* Joint profiling of chromatin accessibility and gene expression in thousands of
single cells. *Science* **361**, 1380–1385 (2018).

47.   Mackay, D. S., Bennett, T. M. & Shiels, A. Exome Sequencing Identifies a Missense
Variant in EFEMP1 Co-Segregating in a Family with Autosomal Dominant Primary Open-Angle
Glaucoma. *PLoS One* **10**, e0132529 (2015).

48.   Lim, S.-H. *et al.* CYP1B1, MYOC, and LTBP2 mutations in primary congenital glaucoma
patients in the United States. *Am. J. Ophthalmol.* **155**, 508–517.e5 (2013).

49.   Fuchshofer, R. & Tamm, E. R. The role of TGF-β in the pathogenesis of primary open-
angle glaucoma. *Cell Tissue Res.* **347**, 279–290 (2012).

50.   Scerbo, P. & Monsoro-Burq, A. H. The vertebrate-specific VENTX/NANOG gene
empowers neural crest with ectomesenchyme potential. *Sci Adv* **6**, eaaz1469 (2020).

51.   Kumar, S., Kumar, V., Li, W. & Kim, J. Ventx Family and Its Functional Similarities with
Nanog: Involvement in Embryonic Development and Cancer Progression. *Int. J. Mol. Sci.* **23**,
(2022).

52.   Fadini, G. P. *et al.* Reduced endothelial progenitor cells and brachial artery flow-mediated
dilation as evidence of endothelial dysfunction in ocular hypertension and primary open-angle
glaucoma. *Acta Ophthalmol.* **88**, 135–141 (2010).

53.   Su, W.-W. *et al.* Glaucoma is associated with peripheral vascular endothelial dysfunction.
Ophthalmology **115**, 1173–1178.e1 (2008).

54.   Green, K. J., Getsios, S., Troyanovsky, S. & Godsel, L. M. Intercellular junction assembly,
dynamics, and homeostasis. *Cold Spring Harb. Perspect. Biol.* **2**, a000125 (2010).

55.   Pattabiraman, P. P., Epstein, D. L. & Rao, P. V. Regulation of Adherens Junctions in
Trabecular Meshwork Cells by Rac GTPase and their influence on Intraocular Pressure. *J. Ocul.*
Biol. Dis. Infor. **1**, (2013).

56.   Gould, D. B., Smith, R. S. & John, S. W. M. Anterior segment development relevant to
glaucoma. *Int. J. Dev. Biol.* **48**, 1015–1029 (2004).

57.   Pasquale, L. R. *et al.* CDKN2B-AS1 genotype-glaucoma feature correlations in primary
open-angle glaucoma patients from the United States. *Am. J. Ophthalmol.* **155**, 342–353.e5
(2013).

58.   Wang, H. *et al.* Physiological function of myocilin and its role in the pathogenesis of
glaucoma in the trabecular meshwork (Review). *Int. J. Mol. Med.* **43**, 671–681 (2019).

59.   Hukku, A. *et al.* Probabilistic colocalization of genetic variants from complex and
molecular traits: promise and limitations. *Am. J. Hum. Genet.* **108**, 25–35 (2021).

60.   Wallace, C. Eliciting priors and relaxing the single causal variant assumption in
colocalisation analyses. *PLoS Genet.* **16**, e1008720 (2020).

61.   Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex
trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).

62.   Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in
Mendelian randomization studies. *Hum. Mol. Genet.* **27**, R195–R208 (2018).

63.   Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).

64.   Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).

65.   Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes across
the human body by integration of single-cell profiles and human genetics. *bioRxiv*
2021.03.19.436212 (2021) doi:10.1101/2021.03.19.436212.

66.   Slowikowski, K., Hu, X. & Raychaudhuri, S. SNPsea: an algorithm to identify cell types,
tissues and pathways affected by risk loci. *Bioinformatics* **30**, 2496–2497 (2014).

67.   Calderon, D. *et al.* Inferring Relevant Cell Types for Complex Traits by Using Single-Cell
Gene Expression. *Am. J. Hum. Genet.* **101**, 686–699 (2017).

68.   Stamer, W. D. & Acott, T. S. Current understanding of conventional outflow dysfunction in
glaucoma. *Curr. Opin. Ophthalmol.* **23**, 135–143 (2012).

69.   Goel, M., Picciani, R. G., Lee, R. K. & Bhattacharya, S. K. Aqueous humor dynamics: a
review. *Open Ophthalmol. J.* **4**, 52–59 (2010).

70.   Alarcon-Martinez, L. *et al.* Pericyte dysfunction and loss of interpericyte tunneling
nanotubes promote neurovascular deficits in glaucoma. *Proc. Natl. Acad. Sci. U. S. A.* **119**,
(2022).

71.   Wang, R., Seifert, P. & Jakobs, T. C. Astrocytes in the Optic Nerve Head of
Glaucomatous Mice Display a Characteristic Reactive Phenotype. *Invest. Ophthalmol. Vis. Sci.*
58, 924–932 (2017).

72.   Zhao, X., Sun, R., Luo, X., Wang, F. & Sun, X. The Interaction Between Microglia and
Macroglia in Glaucoma. *Front. Neurosci.* **15**, 610788 (2021).

73.   Shinozaki, Y. & Koizumi, S. Potential roles of astrocytes and Müller cells in the

pathogenesis of glaucoma. *J. Pharmacol. Sci.* **145**, 262–267 (2021).

74.   Tovar-Vidales, T., Wordinger, R. J. & Clark, A. F. Identification and localization of lamina

cribrosa cells in the human optic nerve head. *Exp. Eye Res.* **147**, 94–97 (2016).

75.   Lopez, N. N., Clark, A. F. & Tovar-Vidales, T. Isolation and characterization of human

optic nerve head astrocytes and lamina cribrosa cells. *Exp. Eye Res.* **197**, 108103 (2020).

76.   Tamm, E. R., Ethier, C. R. & Lasker/IRRF Initiative on Astrocytes and Glaucomatous

Neurodegeneration Participants. Biological aspects of axonal damage in glaucoma: A brief

review. *Exp. Eye Res.* **157**, 5–12 (2017).

77.   Paula, J. S., O'Brien, C. & Stamer, W. D. Life under pressure: The role of ocular cribriform

cells in preventing glaucoma. *Exp. Eye Res.* **151**, 150–159 (2016).

78.   Venkataraman, S. T., Flanagan, J. G. & Hudson, C. Vascular reactivity of optic nerve

head and retinal blood vessels in glaucoma--a review. *Microcirculation* **17**, 568–581 (2010).

79.   Zeng, H.-L. & Shi, J.-M. The role of microglia in the progression of glaucomatous

neurodegeneration- a review. *Int. J. Ophthalmol.* **11**, 143–149 (2018).

80.   Kim-Hellmuth, S., Aguet, F. & Oliva, M. Cell type–specific genetic regulation of gene

expression across human tissues. (2020).

81.   van der Wijst, M. *et al.* The single-cell eQTLGen consortium. *Elife* **9**, (2020).

82.   Li, Y. I. *et al.* Annotation-free quantification of RNA splicing using LeafCutter. *Nat. Genet.*

50, 151–158 (2018).

83.   Pruim, R. J. *et al.* LocusZoom: regional visualization of genome-wide association scan

results. *Bioinformatics* **26**, 2336–2337 (2010).

84.   Zheng-Bradley, X. *et al.* Alignment of 1000 Genomes Project reads to reference assembly

GRCh38. *Gigascience* **6**, 1–8 (2017).

85.   Pividori, M. *et al.* PhenomeXcan: Mapping the genome to the phenome through the

transcriptome. doi:10.1101/833210.

86.   Brown, A. A. *et al.* Predicting causal variants affecting expression by using whole-genome

sequencing and RNA-seq from multiple human tissues. *Nat. Genet.* **49**, 1747–1751 (2017).

87.   Finak, G. *et al.* MAST: a flexible statistical framework for assessing transcriptional

changes and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol.* **16**,

278 (2015).

88.   Lakkis, J. *et al.* A joint deep learning model enables simultaneous batch effect correction,

denoising, and clustering in single-cell transcriptomics. *Genome Res.* **31**, 1753–1766 (2021).

89.   Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait-associated

genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* **49**, D1311–D1320

(2021).

90.   Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. *Proc. Natl.*

Acad. Sci. U. S. A. **100**, 9440–9445 (2003).

91.   Gamazon, E. R., Huang, R. S., Dolan, M. E., Cox, N. J. & Im, H. K. Integrative genomics:

quantifying significance of phenotype-genotype relationships from multiple sources of high-

throughput data. *Front. Genet.* **3**, 202 (2012).

92.   Pollack, S. *et al.* Multiethnic Genome-Wide Association Study of Diabetic Retinopathy

Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. *Diabetes* **68**,

441–456 (2019).

93.   Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or

without a reference genome. *BMC Bioinformatics* vol. 12 (2011).